

# Consortium Agreement for the REACH Registration of Sodium Tri Poly Phosphate (STPP)

pursuant to requirements of the European REACH Regulation

## TABLE OF CONTENTS

<b>Members</b> .....	<b>3</b>
<b>Preamble</b> .....	<b>4</b>
<b>Copyright</b> .....	<b>4</b>
<b>I) Definitions</b> .....	<b>5</b>
<b>II) The purpose</b> .....	<b>7</b>
II. 1) REACH Registration preparation.....	7
II. 2) Management of access to the REACH Registration Dossier .....	8
<b>III) Membership</b> .....	<b>8</b>
III. 1) Admission of new Members to the Consortium .....	8
III. 2) Transfer of membership .....	9
III. 3) Termination of Membership .....	10
III. 4) Exclusion .....	10
III. 5) Common provisions on termination and exclusion.....	11
<b>IV) Confidentiality</b> .....	<b>11</b>
<b>V) Ownership of data</b> .....	<b>12</b>
V. 1) Obligation to make available data .....	12
V. 2) Ownership rights and uses of Information .....	13
V. 3) Third party access to Information .....	14
<b>VI) VI. Organisation</b> .....	<b>15</b>
VI. 1) Legal personality.....	15
VI. 2) Organisation .....	15
VI. 3) Governing Committee.....	15
VI. 4) Not applicable .....	16
VI. 5) Technical Committee .....	16
VI. 6) Not applicable .....	17
VI. 7) The Secretariat .....	17
VI. 8) Delegations of powers and representation to third parties .....	18
VI. 9) Working language.....	19
VI. 10) Rules on voting, quorum and meeting organisation .....	19
<b>VII) Lead Company</b> .....	<b>21</b>
<b>VIII) Individual obligations</b> .....	<b>21</b>
<b>IX) Competition law compliance</b> .....	<b>22</b>
<b>X) Definition of costs and cost allocation</b> .....	<b>22</b>
X. 1) Valuation of Studies.....	22
X. 2) Cost sharing principles .....	22
<b>XI) Administration &amp; Reporting of costs</b> .....	<b>23</b>
<b>XII) Limitation of liability</b> .....	<b>23</b>
<b>XIII) Duration, termination, modification</b> .....	<b>24</b>
<b>XIV) Dispute resolution and applicable law</b> .....	<b>24</b>

<b>XV) Signatures</b> .....	<b>25</b>
<b>Annex 1 - Substance identification</b> .....	<b>26</b>
1. The Substance.....	26
2. Impurities: .....	26
<b>Annex 2 – Identified Uses</b> .....	<b>27</b>
1. Non confidential uses .....	27
2. Confidential uses .....	28
3. Identification of “confidential” uses .....	28
<b>Annex 3 – Not applicable - company information</b> .....	<b>28</b>
<b>Annex 4 – Affiliates of Members</b> .....	<b>29</b>
<b>Annex 5 – Existing Studies</b> .....	<b>30</b>
<b>Annex 6 – Specified external experts</b> .....	<b>33</b>
<b>Annex 7 – Typical current costs of Studies and tests</b> .....	<b>33</b>
<b>Annex 8 – Valuation and access to information</b> .....	<b>34</b>
1. Scientific evaluation .....	34
2. Calculation of value .....	35
3. Indicative summary table: Rules of access .....	36
<b>Annex 9 – Financial rules</b> .....	<b>37</b>
1a. General financial rules.....	37
1b. Indicative summary table : Payments due for Membership and/or Dossier access	39
2. Administration Fee.....	40
3. Advantage Compensation Payment:.....	40
4. Consortium Entry Fee:.....	40
5A). Pro Rata Share: .....	41
5B). Cost sharing mechanism: one Member = one share .....	41
5C). Costs included in Pro Rata Share costs .....	42
5D). Rules for company costs .....	42
6. Dossier Contribution Costs:.....	42
7. Financial contributions in case of leaving the Consortium .....	43
8. Consortium accounting system and payments.....	43
<b>Annex 10A – Model Letter of Access (for Members)</b> .....	<b>45</b>
<b>Annex 10B – Model Letter of Access (Non Members)</b> .....	<b>46</b>
<b>Annex 11 – Consortium preparatory work costs</b> .....	<b>47</b>

# Sodium Tri Polyphosphate Consortium Agreement

This Agreement is signed between the following Members:

Note: conform to §I below (“Definitions”), one “Member” may cover a number of legal entities which are separate REACH Registrants (each paying its own Registration Fee), if and only if each of these legal entities is an “Affiliate” (see Definitions) of this Member, and in this case this Member is treated as a single unit in all aspects of this Agreement: one vote, one share in cost sharing, etc ... Affiliates of Members as at the date of Entry into Force are listed in **Annex 4**.

## Members

At the date of Entry into Force of this Agreement

1) **BK Giulini GmbH**, a company with limited liability under German law (Gesellschaft mit beschränkter Haftung), whose registered office is at Giulinistrasse 2, 67065 Ludwigshafen am Rhein, Germany,

Tonnage band: > 1 000 tonnes/year

and 2) **Chemische Fabrik Budenheim KG** a limited partnership under German law (Kommanditgesellschaft) whose registered office is at Rheinstrasse 27, D-55257 Budenheim, Germany,

Tonnage band: > 1 000 tonnes/year

and 3) **FMC Foret S.A.**, a company with limited liability under Spanish law (sociedad anonima) whose registered office is at Plaza Xavier Cugat, 2, Edificio C, planta 3ª, Parque de Oficinas Sant Cugat Nord 08174 Sant Cugat del Vallés (Barcelona), Spain,

Tonnage band: > 1 000 tonnes/year

and 4) **Prayon SA**, a company with limited liability under Belgian law (société anonyme) whose registered office is at Rue J. Wauters 144, B-4480 Engis, Belgium BCE 0405 747 040,

Tonnage band: > 1 000 tonnes/year

and 5) **Thermphos International BV**, a private company with limited liability under Netherlands law (Besloten Vennootschap) whose registered office is at Europaweg Zuid, Haven 9890, 4389 PD Ritthem, The Netherlands,

Tonnage band: > 1 000 tonnes/year

NOTE: Nilefos not signatory

## Preamble

Whereas the Members (see Definitions) are Manufacturers / Importers / Only Representatives, as defined in REACH, of the Substance described in Annex 1 with registered head offices or affiliates in the European Union.

Whereas the Substance has phase-in status according to Article 3 (20) of REACH and each of the Members intends to pre-register the substance individually or via a representative.

Whereas REACH imposes on Manufacturers and Importers an obligation to register the Substance as such, in preparations or in articles within the prescribed deadlines.

Whereas REACH requires, subject to certain exceptions, multiple registrants of the same substance to share certain data and jointly submit part of the registration relating to the substance.

Whereas considering the effort required by the regulatory obligations the Members wish to increase the efficiency of generation of Information, to avoid to duplicate work and to reduce associated costs as well as to file a harmonised set of data to the European Chemicals Agency.

Therefore, with a view to fulfilling their regulatory obligations, the Members form by the present a Consortium (see Definitions) in respect of anti-trust and competition legislation, open to any other interested operators subject to the criteria defined hereunder, in order to achieve the Purpose (defined in § II), and in particular to:

- share Information, review the available data, identify data gaps, propose additional testing, and, subject to an agreement on a case-by-case basis, perform testing where necessary,
- compile and submit a harmonised set of data and for Registration and a Registration Dossier,
- manage Pre-Registration, Registration and access to this REACH Registration Dossier and to relevant data before and after the Date of Registration, in particular with relation to: other potential REACH Registrants of the Substance, potential REACH Registrants of other substances with potential read-across to/from the Substance, any other party wishing to access or use this dossier for REACH or for any other regulatory purposes,
- carry out other joint activities necessary for the REACH Registration of the Substance or relevant to or related to the Purpose.

## Copyright

This Agreement text is based on the model text developed by Cefic for its member companies and Sector Groups, modified by the Members and by experts commissioned by these Members. This text is thus copyright and property of Cefic and of the Members, and no part of it may be copied or used for other purposes without written authorisation from both Cefic and from the Secretariat.

The Members have agreed the following:

## I) Definitions

The following terms and expressions shall have the meaning assigned to them below:

**Administration Fee:** see Annex 9;

**Advantage Compensation Payment:** see Annex 9;

**Affiliates:** any legal entity controlling, controlled by, or under common control with a Member. For these purposes, "control" shall refer to: (i) the possession, directly or indirectly, of the power to direct the management or policies of a person, whether through the ownership of voting rights, by contract or otherwise; or (ii) the ownership, directly or indirectly, of 50 % or more of the voting rights or other ownership interest of a person. The list of Affiliates as at the date of Entry into Force of this Agreement and conditions for updating this list are included in Annex 4;

**Agency:** the European Chemical Agency;

**Agreement:** this contract between the Members;

**Annex:** refers to an Annex of this Agreement;

**Confidential Information:** see §.IV;

**Consortium:** the Members acting together within this Agreement as specified in § VI.1;

**Consortium Entry Fee:** see Annex 9;

**Core Data:** the data that Members gather, develop in common and agree to submit to the Agency pursuant to Article 11 paragraph 1 of the REACH Regulation, including the following data:

- Classification and labelling of the Substance pursuant to section 4 of Annex VI of REACH;
- Study summaries of the information derived from the application of Annexes VII to XI of REACH;
- Robust Study summaries of the information derived from the application of Annexes VII to XI, if required in Annex I of REACH;
- Proposals for testing where listed in Annexes IX and X of REACH;
- Chemical Safety Report (including chemical safety assessment) as required under Article 14 of REACH, in the format specified in Annex I of REACH;
- Guidance on safe use of the Substance as specified in section 5 of Annex VI of REACH.

it is noted that information on manufacturing processes, substance impurities (see Annex 1.2) and confidential uses (see Annex 2.2) will be submitted separately in each company's specific Registration information;

**Date of Leaving:** see § III.3 and §III.4;

**Date of Registration:** date on which a Registration Number is received from the Agency by the Lead Company, following submission of the Registration Dossier;

**Deadlines for registration:** the date by which the Substance must be registered at the latest as specified in Article 23 of the REACH Regulation;

**Dossier Contribution Cost:** see Annex 9;

**Entry into Force:** date on which this Agreement has been signed by all of the signatories listed in § XV. If the signatories sign on different dates, this means the date of signature of the last of the signatories;

**Identified Uses:** of the Substance are those defined in Annex 2.1 of this Agreement, as referred to in Article 3, sub 26 of the REACH Regulation;

**Information:** Studies, other scientific, statistical, commercial or technical data, including but not limited to Core Data and other data concerning composition, characteristics, properties and processes and uses, and any Information in any form made available to the Members by a Member (including its employees, Affiliates or agents) or by any third party, or generated by the Members individually or jointly. The term Information comprises relevant information that has been exchanged or generated pursuant to or in the course of this Agreement, or prior to the Entry into Force of this Agreement;

**Existing Information:** Information which was NOT generated by the activities covered by this Agreement, that is

- Information which existed prior to the Entry into Force and was not generated in the joint activities of the Initial Members during the phase of establishing this Agreement (late 2007, early 2008);
- Information which was generated by third parties, independently of this Agreement, before or after the Entry into Force;
- in particular, the Studies listed in Annex 5;

**Governing Committee:** see § VI.3;

**Joint Submission:** as defined in Article 11 of the REACH Regulation.

**Key study:** a study considered as the “key study” as defined in the Agency “Guidance for the Implementation of Reach, Guidance on Data Sharing, September 2007”.

**Lead Company:** the Member who is responsible for submitting the Core Data to the Agency on behalf of the Members and their Affiliates pursuant to Article 11 (1) of REACH;

**Letter of Access:** as per models in Annex 10A and Annex 10B.

**Member(s):** the Initial Members (see below) as well as any Manufacturers / Importers / Only Representatives, as defined in REACH, of the Substance which become signatories to this Agreement in future as specified in § III of this Agreement;

**Membership:** being a Member as defined above;

**Initial Members:** the Manufacturers / Importers / Only Representatives, as defined in REACH, of the Substance which are signatories of this Agreement (that is, all the signatories in § XV except the Secretariat) at the date of Entry into Force;

**Voting Member:** (representative of a) Member who is part of a given Committee or Task Force and is not excluded from voting on a given issue;

**Pro Rata Share:** see Annex 9;

**Purpose:** as defined above under Preamble and in § II;

**REACH:** the REACH Regulation N° 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (OJ L 396 of 30.12.2006), and also all subsequent regulations, decisions, guidelines and rules defining the implementation of this Regulation;

**Registration:** REACH Registration of a substance, as defined in Article 10 of the REACH Regulation;

**Registration Dossier:** all Information, Studies, summaries of Studies, data, documents collected and collated for the REACH Registration of the Substance and submitted to or held available to the Agency, and in particular including the Core Data (see above);

**Secretariat:** see § VI.7;

**Study:** reports, tests or evaluations in written or electronic form, including full study reports, summaries and robust study summaries as defined by REACH, relating to properties, exposure

assessment, environmental or biological behaviour and/or impacts, and/or risk characterisation of the Substance and which are of relevance for Registration;

**Substance:** for the purpose of this Agreement, is defined in Annex 1;

**Task Force:** a working group made up of the Members, as defined in § VI.2;

**Technical Committee:** see § VI. 5;

**Tonnage band:** as defined in REACH, article 12;

and otherwise **any definitions specified in REACH**, in particular in Article 3 of the REACH Regulation, shall apply to this Agreement.

## II) The purpose

### II. 1) REACH Registration preparation

The Members of the Consortium undertake to cooperate and share human and financial resources in order to comply with the requirements of REACH for the Substance and in particular to pursue jointly the following objectives:

- (1a) define and agree the identity and the sameness of the Substance and its regulatory status
- (1b) develop Core Data for the Substance fulfilling the highest tonnage band requirements applicable to at least one of the Members, including where appropriate the following actions:
  - Gather and assess available data on the Substance held by the Consortium Members or by third parties as well as data in the public domain (literature etc.);
  - Identify data gaps between the available data and the requirements in Annexes VI to XI of REACH;
  - Where this is necessary (in view of data gaps for the Substance), appropriate and feasible, define and agree for which other substances the available Information might be relevant for Registration of the Substance, gather and assess available data and develop read-across;
  - Assess opportunities for exposure-based waivers;
  - Subject to obligations under Art. 30 of REACH Regulation carry out testing to close the data gaps identified in relation to Annexes VI to VIII of REACH taking into account Annex XI;
  - Develop testing proposals as required according to Annexes IX and X of REACH taking into account Annex XI;
  - Acquire where necessary Information, and appropriate access rights to this Information, from third parties;
  - Prepare Study summaries and robust Study summaries, where appropriate;
  - Develop uniform classification, and where necessary uniform labelling, conform to applicable legislation;
  - Coordinate the compilation and the submission of the Registration by the Lead Company;
  - Gather information on use and exposure categories of the Substance, conditions of use and exposure to humans and environment for the Identified Uses of the Substance;
  - Perform a risk assessment according to scientific principles and regulatory guidelines with the intention to show a safe production and use of the Substance for the Identified Uses;
  - Initiate testing where a higher tier risk assessment is needed to demonstrate safe manufacturing, transport, handling and use of the Substance in for the Identified Uses.

- (2) Prepare for REACH Pre-Registration of the Substance, which is to be done by each Member or its representative (as required by REACH), prepare a Registration Dossier for the Substance, and prepare all data and information necessary for these purposes
- (3) Mandate the Lead Company to carry out a Joint Submission on behalf of all the Consortium Members and of their Affiliates.
- (4) Coordinate the submission to the Agency of the Core Data by the Lead Company at least three months before the deadline for Registration applicable to the Member(s) within the highest tonnage band.
- (5a) Continue the cooperation between Members relating to Registration of the Substance and consequences of this Registration, after Registration, and in particular during the dossier evaluation according to Title VI of the REACH Regulation, including supervising the performance of the testing proposals as authorised by the Agency.
- (5b) Address legal and technical issues in relation to this Agreement and to the Purpose.
- (6) Prepare and manage Information relevant to the Registration of the Substance, relevant to participation in Substance Information Exchange Forums (SIEF) for the Substance, and relevant to answering enquiries from participants in SIEF for the Substance and for other substances ; including concerning possibilities to apply read-across approaches and (Q)SAR models both to and from other substances, and in particular:
  - Coordinate relations between the Members and other companies in the Substance SIEF concerning all issues relating to Registration of the Substance, or concerning the use of Information developed or collected through this Agreement and/or contained in the Substance Registration Dossier developed through this Agreement;
  - Coordinate relations between the Members and companies, in SIEFs for other substances, who wish to use Information developed or collected through this Agreement and/or contained in the Substance Registration Dossier developed through this Agreement, for read-across for REACH Registration of other substances or for any other purposes;
  - Coordinate relations between the Members and other companies holding information useful for the Purpose;
  - Look for and develop opportunities to obtain compensation for the Information collected and developed through this Agreement in exchange for use of this Information by third parties for Registration of the Substance, of other substances (read-across) or for other purposes.
- (7) Exercise the rights to Information and Studies in accordance with sections IV and V of this Agreement.
- (8) Manage and defend the rights of access, for use in REACH, other regulations or for any other purpose, to the Substance Registration Dossier and to other Information developed through this Agreement, including defining, collecting and distributing payments for the purchase of these access rights.

## **II. 2) Management of access to the REACH Registration Dossier**

See § V.2

# **III) Membership**

## **III. 1) Admission of new Members to the Consortium**

1. All conditions to access the Consortium, and in particular all financial conditions, shall in all cases be fair and transparent. Membership shall be open to any applicant who fulfils the Membership



criteria defined in this Agreement and is committed, in writing, to pay the financial contribution as defined by this Agreement.

The financial conditions of Membership of the Consortium are defined in Annex 9

2. Application for Membership shall be sent in writing and to the Secretariat which shall then submit such application to the next meeting of the Governing Committee, which shall be called within a reasonable delay and generally if practical within approximately two months. The Parties agree that the acceptance of a new Member is subject to the decision of the Governing Committee (as specified in § VI.10), it being understood that such consent cannot be unreasonably denied.

In any case, the acceptance of a new Member cannot be denied should the applicant fulfil the following objective requirements:

- be at the time of requesting Membership a manufacturer of the Substance in the European Union, or an importer of the Substance into the European Union) in quantities susceptible to require REACH Registration, or be susceptible to begin such an activity in the future ; or be an “Only Representative” of such a company
- and have committed in writing to fulfil all the conditions of this Agreement, and in particular the financial conditions indicated in Annex 9

It is here noted that, by Article 7 of the REACH Regulation and according to tonnage bands, under “importer of the Substance” are included importers of detergents and/or other formulations containing the Substance, where the Substance “is intended to be released under normal or reasonably foreseeable conditions of use”.

Note: access to the Registration Dossier, data and information developed under this Agreement is possible, without becoming a Member of the Consortium, according to the conditions specified in V.3

3. Any decision refusing Membership shall clearly state the reasons why the Membership is not granted. The applicant whose application was turned down has the right to submit its observations in writing to the Governing Committee, which shall have to review the observations and reply in writing within a reasonable delay and generally if practical within approximately two months of receiving the observations. If there is disagreement and an amicable solution cannot be found, then the applicant shall be invited to submit the issue to arbitration as provided in § XIV.
4. A new Member shall commit in writing to the terms and conditions as set out in this Agreement and shall then receive an Access Letter according to the model in Annex 10 A to this Agreement. As from receipt by the Secretariat of all payments due as defined in this Agreement (and in particular in Annex 9), the new Member shall have the same rights and obligations as any existing Member.
5. Membership explicitly implies and necessitates acceptance, by the Member, to make available for the Purpose all relevant Information in its ownership and of which it has information, as specified in § V.1 of this Agreement, unless such information is subject to confidentiality which cannot be waived by such Member.

### **III. 2) Transfer of membership**

1. A Member shall be entitled to transfer Membership including all its rights and obligations under the Agreement to a third party subject to:
  - requesting the transfer in writing to the Secretariat, specifying clearly the identity of the new Member,
  - the new Member must meet the Membership criteria defined in this Agreement,
  - decision of the Governing Committee (as specified in § VI.10)
  - written acceptance by the new Member of the conditions for Membership defined in this Agreement.

The decision procedures and deadlines are as specified in III.1

2. The consent of the Governing Committee shall not be required in the case of a transfer of Membership in the context of restructuring of legal persons affiliated to or within a Member composed of a group of companies, or in the case of the transfer of ownership of a Member to a new legal entity (take-over, merger, or similar).
3. The transfer by a Member of a part of its rights or obligations, including financial claims, to a third party shall not be permitted, unless decided by the Governing Committee.

### **III. 3) Termination of Membership**

1. At any time, a Member can terminate its Membership in the Consortium if circumstances making the continued Membership in the consortium disproportionate or unjustified have durably occurred provided that the Member fulfills all of its financial obligations to the Consortium and to the other Members. In this case, the Member must provide three months prior written notice to the Secretariat.
2. At any time, a Member can terminate its Membership in the Consortium without justification, provided that it has fulfilled all of its financial obligations as specified in Annex 9. In this case, the Member must provide one year prior written notice to the Secretariat
3. The Date of Leaving is the date of expiry of the written notice period specified above, which runs from the reception of the notification by the Member to the Secretariat of the termination of Membership.

### **III. 4) Exclusion**

1. Any Member, that
  - does not meet durably the Membership conditions of this Agreement,
  - fails to make payments due within the delay specified in Annex 9 and fails to correct this situation within 15 days of receiving a written reminder from the Secretariat,
  - or commits a serious material breach of this Agreement that has not been repaired within 30 calendar days after formal notice has been sent by the Secretariat by registered mail to the Member concerned,
  - or does not durably comply with the provisions of this Agreement such that this non-compliance has affected the effectiveness of the Consortium in achieving the Purpose, or has affected the functionality and reliability of the Information collection process, and/or has caused damages to the other Members,

may be excluded from the Consortium, as follows, without prejudice to any other rights the Members may have against the defaulting Member.

2. The defaulting Member may be excluded by decision of the Governing Committee (as specified in § VI.10) and on the basis of an objective and documented justification in compliance with Articles 81 and 82 of the EC Treaty. The defaulting Member shall have the right to present its defence beforehand. The decision of the Governing Committee shall be immediately notified to the defaulting Member by registered mail.
3. The non-defaulting Members will share any damages suffered by the Consortium as a result of the defaulting Member, according to the cost sharing rules indicated in Annex 9, and the Consortium (as specified in § VI.8) shall coordinate any legal recourse against the defaulting Member on behalf of the non defaulting Members.
4. The Date of Leaving will be the date of receipt by the Member of the registered mail specified above.

### III. 5) Common provisions on termination and exclusion

1. Subject to the conditions specified hereafter, termination or exclusion of a Member (both as above) are without prejudice to the rights and obligations of the Member that is terminating its Membership or is excluded (hereafter **Member leaving**) which have accrued up to the date of effective termination or exclusion provided that the Member leaving meets all payment obligations for the period of Membership and payment obligations due after ceasing to be a Member as specified in this Agreement. The Member leaving shall have no further rights to any results arising out of this Agreement in respect of which it has not fulfilled its financial contribution or to any compensation from new Members that have subsequently joined the Consortium for information and Studies developed before cessation of its Membership.
2. The other Members shall continue to be entitled to make use of the Information made available by the Member leaving on the conditions specified in this Agreement and provided that the Member leaving has been duly compensated under the conditions defined in this Agreement. Any recoverable damages suffered by the remaining Members as a result of the defaulting Member's actions shall be off set against any compensation payable to the Member leaving.
3. The Member leaving shall have no claims for reimbursement of any financial contribution to the Consortium.
4. The Member leaving shall remain liable for the activities undertaken under this Agreement for the period of its Membership, and for ongoing activities at the time of leaving as specified in Annex 9.
5. In the event of termination or exclusion, the rights and obligations resulting from this Agreement cease to exist, to the exception of, as defined in this Agreement, confidentiality commitment and data ownership, liability as defined in § XIII.2, settlement of disputes, and any outstanding financial obligations. In particular, the confidentiality conditions specified in § VI remain applicable to the Member leaving.
6. In particular, leaving the Consortium does not negate or remove the entitlement of the Member leaving to continue to use for itself and for its Affiliates only, under the conditions defined in this Agreement, those parts of the Registration Dossier and other Information which were developed by the Consortium during the period in which the leaving Member complied with its financial obligations as defined in this Agreement and/or for which the leaving Member contributed financially under this Agreement.
7. A Member having left the Consortium cannot sell or transfer in any way to third parties, other than its Affiliates, without approval from the Consortium, any Information developed by the Consortium, the Registration Dossier developed by the Consortium, nor any rights of access to these.

## IV) Confidentiality

1. Subject to the conditions below the Members, unless compelled by law or a legally empowered authority, or unless legal disclosure requirements apply, undertake to keep confidential, as specified below, any information other than as specified hereafter, which is:
  - directly or indirectly belonging or relating to other Members,
  - disclosed by another Member pursuant to or in the course of this Agreement,
  - or jointly developed, obtained from a third party or otherwise resulting from this Agreement.

Such information, except as specified in § IV.7 and § IV.8, is termed "**Confidential information**".

2. Each Member shall advise immediately the other Members in writing of any disclosure or misuse by any Member or a third party of Confidential Information, as well as of any request by competent authorities relating to the disclosure of such information.

3. Disclosure of results in Studies as required for legal and/or regulatory purposes including the REACH Regulation, shall only take place by the Members in a form (for example short summaries where possible) reflecting the minimum information required to be disclosed.
4. The above restrictions do not apply to the Member who has provided or who owns the Confidential Information.
5. Members may use Confidential Information only for the Purpose or otherwise as permitted under or in accordance with this Agreement, or as authorised by the owner of the information.
6. Members will disseminate Confidential Information to their employees, Affiliates or external experts and/or consultants only on a need to know basis and only to the extent absolutely necessary for the Purpose or otherwise as permitted under or in accordance with this Agreement. Each Member shall have in place policies and procedures to ensure the confidentiality of information, computer files and documents, and require that its external experts and/or consultants also have such policies and procedures in place to ensure their compliance with these confidentiality obligations.
7. The obligations specified above shall not apply to Information for which the receiving Member can reasonably demonstrate that such information:
  - a) was known to the receiving Member on a non-confidential basis prior to its disclosure pursuant to this Agreement;
  - b) is publicly known at the time of disclosure or thereafter becomes publicly known without breach of the terms of this Agreement;
  - c) becomes non-confidential through disclosure by sources other than the disclosing Member, having a right to disclose such Information,
  - d) was independently developed by the receiving Member without access to the disclosing Member's Information, as evidenced by documentary records,
  - e) becomes subject to disclosure to governmental agencies or other authorities which then render the Information non confidential.
8. Specific items of information shall not fall within any exception merely because they are combined with other information falling within any exception. Likewise, any combination of specific items of information shall not fall within any exception merely because the specific items fall within any exception, but only if the combination itself, and its principles of operation, fall within any exception.
9. Affiliates and external experts and/or consultants (if bound by a confidentiality agreement) of any Regular Member are not regarded as third parties for the purpose of this § IV. Each Member assumes full responsibility for compliance by its employees, Affiliates or external experts and/or consultants with the requirements of this Agreement in the respect of any Information received by this party, unless the party in question is also a signatory of this Agreement.
10. In the event of non-compliance with the obligations set out in this § IV the Members whose Information is disclosed shall have the remedies available under the applicable law notwithstanding the stipulations contained in this Agreement.
11. The duration of the above confidentiality obligations is defined in § XIII.

## **V) Ownership of data**

### **V. 1) Obligation to make available data**

1. Within 6 weeks of a new Member joining the Consortium, it shall make available to the Secretariat a list of all Information it owns, has access to and/or has knowledge of, which is relevant to the Purpose, including Information concerning the uses and conditions of use of the Substance within the Identified Uses (Annex 2). The obligation to list the Information applies even if the Information itself is confidential, unless the simple listing of the knowledge would be contradictory to confidentiality conditions which the Member cannot waive. This list can take the form of indicating

only Information which is additional or new to that already listed by the Secretariat, or for which the new Member has ownership or access rights additional to the rights already available to the Consortium. The Secretariat shall make the necessary arrangements for the review of this Information by the Technical Committee.

It is noted that the Initial Members of the Consortium have already fulfilled this obligation prior to the Entry into Force of this Agreement. The principal elements of Information thus provided are listed in Annex 5 ("Existing Studies").

2. All Members agree to make available to the Secretariat, to the other Members and to third parties purchasing access to all or to part of the REACH Registration Dossier developed within this Agreement, according to the conditions defined in this Agreement, and in particular in Annex 8 (Study valuation), Annex 9 (Financial Rules) and Annexes 10A and 10B (Model letters of access):
  - all Existing Information and any new Information relevant for the Registration of the Substance, for which they have or come to have ownership or right of access entitling them to do so, and which are relevant for the Purpose,
3. All Members agree to inform the Secretariat and the Lead Company of any contact or communication from third parties wishing to access the Registration Dossier developed under this Agreement, or Information therein or developed by the Consortium, or otherwise wishing to share Information, join or cooperate with the Consortium, or develop other relations with the Consortium

## V. 2) Ownership rights and uses of Information

The following clauses are subservient to any requirements specified by REACH, by its official Guidance documents, by the Agency, and to any other applicable European or international regulations or laws:

1. Members will be entitled to use and refer to the Registration Dossier developed within this Agreement, except as specified hereafter, **for purposes of REACH Registration of the Substance only.**

Members will however be entitled to use, for their own use and the use of their Affiliates, Information newly developed by activities carried out within this Agreement **for all regulatory or other purposes.**

Unless specifically agreed otherwise with the owner, Members will be entitled to use Existing Information collected within this Agreement (owned by a Member or a third party) for purposes of REACH Registration of the Substance only.

2. The above does NOT affect the copyright and ownership of Studies and data developed outside this Agreement by Members, owned by Members or by third parties.

Members wishing to use such Information, must ensure that they have the necessary authorisation from the data owners, unless this authorisation for the relevant use is obtained and covered by an agreement between the data owners and the Consortium.

Any intellectual property or ownership rights to any Existing Information independently developed by a Member or any third party and made available to the Members in accordance with this Agreement shall remain unaffected by this Agreement. The (other) Members shall have for an indefinite period of time the non-transferable right to use the Information for the Purpose, including the right to refer to the full Study report, provided that they share in its cost in accordance with the cost allocation method defined in this Agreement.

The Study made available by a Member or a third party to other Members may not be sub-licensed or otherwise made available to third parties without prior written approval of the Member who provided the Study.

The Member who provided a Study to other Members may extend, by agreement in writing, at a cost or free of charge, their right to use or refer to the Study for other purposes.

Existing Studies which are owned by several Members or by one or several Members and one or several third parties can only be made available to the other Members with the prior written approval of all owners unless otherwise agreed in writing among the owners of the Study.

3. Conditions concerning third parties wishing to use the REACH Registration Dossier developed within this Agreement, or a part of this dossier, and/or any other Information developed within this Agreement are defined in § V.3.
4. The Members mandate the Governing Committee (as per definition of powers in § VI.8) to manage on their behalf all such authorisations, and the Secretariat to collect and to redistribute appropriately all payments relating to these authorisations.
5. Any Information generated or developed within this Agreement shall be owned jointly by the Members provided that the individual Members have contributed to the costs thereof in accordance with the cost allocation method defined in this Agreement. Each of the joint owners shall obtain a copy of the full Study reports. The Information referred to in the first sentence may be used by the Members who have contributed to the costs thereof for the Purpose and also for fulfilling their own other regulatory and legal requirements (under REACH and other regulations, European, national or other regulations, for the Substance and for other substances), but such Information shall not, for the period defined for duration of confidentiality under § XIII, be sold, licensed or otherwise made available to third parties by any Member unless as decided by the Governing Committee (as specified in § VI.10)
6. Affiliates of a Member shall have the same rights on Information under the same conditions as the Member to which they are affiliated.
7. Neither this Agreement nor any disclosure of Information shall be deemed by implication or otherwise to vest in one Member any present or future rights in any patents, trade secrets or property rights in data belonging to another Member and no licence is granted except as explicitly stated in this Agreement.

The conditions of access to Information are further specified in Annex 8.

### **V. 3) Third party access to Information**

Third parties may be granted rights to use or refer to the parts or totality of the Registration Dossier, or to any other Information generated by or owned by the Consortium Members jointly, including any Information for which the use granted by its owner to the Consortium Members jointly enabled such transfer of rights, subject to the financial conditions defined in Annex 9.

In particular, any potential REACH Registrant of the Substance, including the applicants for Membership whose application was refused, may request a right to use or to refer to the parts or all of the Registration Dossier to the extent the Members of the Consortium are entitled to do so.

Where granted, such right will be non-exclusive and non-transferable.

Access will not be granted to data not owned by the Members, unless this has been agreed with the original owner.

Subject to the terms of this Agreement, the Governing Committee shall take a decision (as specified in § VI.10) whether or not to grant such rights to a third party and determine the amount of compensation payable in accordance with Annex 9. This decision will be taken without undue delay..

The terms and conditions of access will be set out in each case specifying the exact scope in accordance with the model Letter of Access attached in Annex 10B.

## **VI) VI. Organisation**

### **VI. 1) Legal personality**

This Agreement and the cooperation contemplated herein shall not constitute or be deemed to constitute a legal entity between the Members nor make a Member the agent or representative of another Member unless expressly stated otherwise.

In its external relations, the Consortium will not act under its own name but as a community of all its Members. The Members hold the rights and obligations of the Consortium jointly.

### **VI. 2) Organisation**

The bodies of the Consortium will be the Governing Committee and the Technical Committee.

The Consortium shall be governed by the Governing Committee.

In order to fulfil the Purpose, the Governing Committee shall be empowered to set up and define the composition, mandate, duration and rules of any necessary Task Forces.

A Secretariat may be appointed, for as long as is decided, as defined below.

Voting and quorum rules for the different committees are specified in § VI.10

### **VI. 3) Governing Committee**

The Members of the Consortium shall meet in the Governing Committee in order to take decisions on the overall organisation of the Consortium. The Governing Committee shall have all powers necessary to ensure that the Purpose is achieved and to take decisions on all issues resulting from this Agreement.

The Governing Committee shall consist of one representative per Member.

The Governing Committee shall jointly elect a Governing Committee Chairman, for a period of two years renewable, preferably from the Lead Company.

Meetings of the Governing Committee shall be convened at least once every six months up until completion of REACH Registration of the Substance, and then at least once every three years or whenever is necessary, to review, on the basis of the technical and financial progress reports of the Secretariat, the progress and developments of the Consortium's work and budget, and more generally all Consortium activities and management issues, or other questions relating to the Purpose.

Meetings of the Governing Committee will also be convened if requested by the majority of the Members, whenever the agreed deadlines or estimated budget are overrun and/or when extraordinary circumstances occur.

The tasks of the Governing Committee include amongst others the following:

- Appointment or ending the appointment of a Secretariat as specified below in § VI.7;
- Directing the Technical Committee;
- Establishing defining and directing Task Forces as required and appropriate;
- Decisions on funding, scope and matters of policy;
- All decisions concerning the financial contributions of Members, including new Members and Members leaving the Consortium or excluded;
- Decisions on the working and finance plan, including outline test plans and strategies for purchasing access to third party Information to fill data gaps;

- Management of financial resources of the Consortium, including deciding budgets, examining and approving accounts, collecting funds and overseeing accountancy and budgets;
- Deciding, conform to Annex 9, which costs engaged by Members, the Secretariat and other parties are included in the budget subject to the cost sharing;
- Coordination and supervision of activities of the Lead Company;
- Mediation in cases of disagreement or disparities within the Technical Committee;
- Modification of any provision as well as the Annexes of this Agreement;
- Adaptation of this Agreement in light of legislative and technical adaptation of the REACH requirements (in particular the establishment of the SIEF) or Entry into Force of the Globally Harmonised System;
- Decision regarding admission, withdrawal and exclusion of Members;
- Decisions regarding access rights to Information and to the Registration Dossier, including deciding contract and other conditions and fixing payments in accordance with Annex 9 ;
- Competition law compliance ;
- Defining rules and modalities concerning communication between all parties involved.

#### **VI. 4) Not applicable**

#### **VI. 5) Technical Committee**

The Technical Committee shall consist of one representative per Member, unless one or more Members do not wish to be represented on this Committee.

The Technical Committee shall jointly elect a Technical Committee Chairman who shall be responsible for the organisation of meetings and who shall report to the Governing Committee. If not, this role will be ensured by the Governing Committee Chairman. Meetings of the Technical Committee shall be convened by its Chairman when necessary to review the progress according to the work schedule and the engagement of costs.

The tasks of the Technical Committee include as necessary and appropriate, amongst others, the following, in all cases subject to respecting the general objectives fixed by the Governing Committee and subject to respecting the budgets decided by the Governing Committee:

- Defining and overseeing the work of the Secretariat;
- Defining and overseeing the technical work;
- Appointment of external consultants to perform technical and scientific tasks;
- Delegating and directing sub-tasks;
- Determining the value of Information;
- Estimate financial resources required to comply with REACH requirements;
- Proposing work plans and outline test plans to the Governing Committee, ensuring execution and quality of results of approved work and test plans;
- Decisions to implement or reject testing proposals;
- Within the outlines and strategies decided by the Governing Committee, decisions on data collection concerning the Substance, evaluating the Substance related Information to be shared, as well as completion of data gaps in compliance with the legal requirements laid down by REACH regarding data sharing, including decisions on purchase of access to third party Information where necessary;
- Overlooking the progress and the budget management, reporting deviations to the Governing Committee;
- Supervising preparation of the Registration Dossier, including the determination of data gaps, waivers and surrogate data;



- Approval of the Registration Dossier and Core Data to be submitted jointly to the Agency (cf. in particular Article 11 of the REACH Regulation) and determination of the Information which shall be subject to a request for confidentiality according to Article 119 of the REACH Regulation;
- Supervising preparation of the Chemical Safety Report (CSR), if required;
- Collecting classification and labelling data from all Members and preparing harmonised classification and labelling in accordance with the Global Harmonised System of classification and labelling of chemicals (GHS);

## **VI. 6) Not applicable**

## **VI. 7) The Secretariat**

A Secretariat may be appointed by the Governing Committee, which can also terminate the appointment of the Secretariat. A Secretariat may be appointed as from the Entry into Force by designation in § XV of this Agreement and its signature by the Secretariat.

The Secretariat is accountable to the Governing Committee.

The Secretariat must be fully independent from all Members (that is: not under legal or financial control of any Member, no significant part of its capital or control held by any company holding significant capital or legal control in a Member ...).

If, at any time, no Secretariat is appointed, or if the Secretariat is not operational, then its tasks and its role as indicated throughout this Agreement will be assumed by the Governing Committee Chairman, who may subcontract part or all of these tasks under the conditions specified below.

The Secretariat may subcontract part of its tasks to other persons or organisations, subject to prior approval of the Governing Committee (as specified in § VI.10) specifying the identification of the subcontractor and the nature and conditions of the tasks subcontracted, and subject to the subcontractor being also independent from all Consortium Members. The legal responsibility for the subcontracted tasks remains with the Secretariat. The legal liabilities of the Secretariat are as specified in § XII

The Secretariat conducts all normal business of the Consortium, subject to the decisions of the Governing Committee and Technical Committee, and is responsible for daily management and external representation of the Consortium and shall in this regard deal particularly with the following:

- Proposing the working and finance plan;
- Organising and convening meetings, distribution of agenda and making minutes, archiving, and distribution of minutes and other information;
- Keeping archives for a minimum period of twelve years and notifying the Members before any archive will be disposed of;
- Ensuring compliance with competition laws;
- Handling where necessary for the Purpose of confidential data (production volumes, markets, confidential uses, etc.)
- Supervision of external consultants and experts;
- Follow up the legislative and technical development of REACH and inform the Technical Committee and Governing Committee about relevant new developments;
- Follow up of progress in the technical activities of the Consortium and reporting on the technical and financial aspects to the Technical Committee and to the Governing Committee;
- Provision of technical and administrative support for the Technical Committee and for other Consortium activities;

- Providing guidance for, coordination of and carrying out of guidance for data collection concerning the Substance, and proposing purchase of rights of access to Information where necessary for the Purpose;
- Performing sub-tasks as agreed by the Technical Committee;
- Processing of purchase orders and contracts for Studies in line with the approved test plans and for other work for Consortium activities;
- Preparing Governing Committee decisions on rights of access of third parties to the Registration Dossier and other Information, including proposing conditions and appropriate levels of payments in accordance with Annex 9;
- Keeping track on ownership, access rights, costs and values of Information (developed within this Agreement, owned by Members or third parties and used for the Purpose), keeping records of compensation due for access rights and other payments due, keeping records of the costs, value and ownership rights of Information generated;
- Keeping an up-dated list of third parties having access rights to Information and to the Dossier developed by the Consortium;
- Handling financial matters including preparing budgets, collecting payments due and making payments, invoicing, managing collected funds, preparing accounts;
- Calculating cost shares and other payments due by and to Members, compensation and payments due by and to third parties;
- Keeping an up-dated list of Members, Affiliates and their representatives;
- Communicating to organisations, associations and potential new Members.

## **VI. 8) Delegations of powers and representation to third parties**

The Governing Committee Chairman is empowered to represent the Members and to sign all documents, contracts and agreements which are in compliance with valid decisions of the Governing Committee, except the following acts for which the Lead Company is empowered to represent the Members and to sign:

- all acts directly concerning the REACH Registration of the Substance, including joint submission of the relevant Information, and including dealing with any regulatory consequences of Registration of the Substance (SIEF, ECHA questions ...);
- Letters of Access or other documents concerning transfer of access rights to the REACH Registration Dossier for the Substance, Information contained within this or developed or obtained within this Agreement.

The Governing Committee may empower the Technical Committee Chairman to sign all documents, contracts and agreements on behalf of the Consortium Members which have been approved by the Technical Committee and which are covered by the powers and tasks of the Technical Committee.

The Governing Committee may empower the Secretariat to sign all documents on behalf of the Consortium Members, in place of the Governing Committee Chairman and of the Lead Company, subject to the following conditions:

- In this case, the Secretariat shall represent the Members for all acts necessary to achieve the Purpose and shall fully and timely comply, on behalf of Members, with the relevant provisions of REACH in this respect;
- the Secretariat may represent the Members in the SIEF if this is possible under the SIEF operating rules and information tools to be established by the Agency. If this representation is not entrusted to the Secretariat, then the Lead Company may be designated to represent the other Members in the SIEF.

Only the Members who are required to submit a Study or data, according to their tonnage band, shall be listed as parties to the relevant agreements and actions, and be liable for the expenses incurred.

Any legal suits shall be brought or defended by the Governing Committee Chairman or a Member or the Secretariat, after authorisation by the Governing Committee as specified in § VI.10. A status report on such litigation shall be presented to the Governing Committee annually.

## **VI. 9) Working language.**

The working language of all Committees, Task Forces and other activities under this Agreement shall be English.

## **VI. 10) Rules on voting, quorum and meeting organisation**

Unless specified otherwise in this Agreement, the following rules apply to meetings and to the decision making of the Governing Committee, Technical Committee and any Task Forces.

### **1. General rules concerning meetings**

Meetings may take place in person, by telephone, video or webcam conferences or similar.

Each Member shall name to the Secretariat the person who is its representative in the Committees and Task Forces. The Member may name a substitute or a different representative before the start of a meeting. These persons must be salaried staff or legal representatives of the Member or of its Affiliates.

The Member's representative may be accompanied by other salaried staff or legal representatives of the Member or its Affiliates, unless another Member present objects to this. Only the Member's representative is entitled to vote.

The external experts indicated in Annex 6 are allowed to participate in meetings without having voting rights. Other third parties may participate at Technical Committee meetings without having voting rights, unless one or more Members object.

Notice of each Governing Committee meeting and the agenda shall be transmitted to each Member at least 21 days in advance; 10 days for the Technical Committee and Task Forces.

No decision can be taken on an item which does not appear on the circulated agenda unless all Voting Members are present and agree at the meeting and/or have agreed prior to the meeting (by email or in writing) to discuss this item.

A written consultation of all Voting Members of a Committee or Task Force can take place by email when a decision cannot be deferred until the following meeting and is not sufficiently important to justify convening a meeting, or when the organisation of a meeting is not feasible because of availability of Voting Members. Except in urgent cases, which must be explicitly indicated, replies must be given, within 21 days for the Governing Committee or 10 days for the Technical Committee and Task Forces. The absence of the reply after a written reminder and within this period shall signify acceptance. Any decision taken by written consultation shall be submitted for confirmation at the subsequent Committee meeting.

### **2. Voting rules: majorities**

A Voting Member which is unable to have a representative (as defined above in § VI.1) present at a meeting may give their proxy vote only to the representative of another Voting Member. One Voting Member, however, may not vote by proxy for more than one other Voting Member (in addition to their own vote). The written proxy shall be presented to the Secretariat before the meeting or at the start of the meeting.

Decisions of the **Governing Committee** shall be taken as follows:

- Unanimous decision of Voting Members (present or represented) is required for:
  - modification of this Agreement or its Annexes (except as specified below);
  - admission of a new Member, transfer of Membership or Membership rights;
  - exclusion of a Member (the Member under discussion does not vote);
  - replacement of the Lead Company (the actual Lead Company does not vote);
  - decisions concerning legal actions brought by/against the Consortium;
  - dissolution of the Consortium and termination of this Agreement at any time before 12 years after the Date of Registration.
- Any modification of the Advantage Compensation Payment (amount, mechanism) can be made only by the unanimous decision of those Initial Members which are still Members at the time of the decision.
- 2/3 majority of Voting Members (present or represented) is required for:
  - fixing the annual budget;
  - appointment, termination or modification of the Secretariat, delegation of the Secretariat's tasks;
  - authorisation of subcontracting by the Secretariat;
  - establishment of, appointment or modification of Task Forces;
  - modification of annexes 10 A and 10 B (terms of Letters of Access);
  - authorisation of sale, rights of access, etc., to the Registration Dossier and Information developed within this Agreement, and payment conditions.
- Simple majority of Voting Members (present or represented) for:
  - financial and budget decisions, except as specified above;
  - modification, according to the procedures indicated in these Annexes, of Annex 2 (Identified Uses), Annex 4 (affiliates), Annex 6 (experts);
  - dissolution of the Consortium and termination of this Agreement after the date indicated above;
  - decision to appeal against any decision by the Agency, or by Member States, relating to the Purpose;
  - all other questions and decisions not specified above.

Decisions of the **Technical Committee and Task Forces** shall be by unanimous vote of Members present or represented at each meeting.

A Member shall be excluded from voting (and not be counted in the "Voting Members" above) in the event of a vote on:

- the exclusion of that Member ;
- on matters in which it has no vested interest, including a vote on testing proposals which it is not required to provide for Registration and of which it does not intend to participate in funding.

### **3. Voting rules: quorum**

All decisions will only be valid if the following a quorum of Voting Members is present or represented:

- for Governing Committee decisions requiring a unanimous vote: 100% of Voting Members,
- for other Governing Committee decisions: 80% of Voting Members
- for Technical Committee and Task Force decisions: 2/3 of Voting Members of the relevant committee

If a Governing Committee meeting is unable to take decisions because the quorum is not achieved, then the Governing Committee Chairman will call a second Governing Committee meeting and this time for the same decisions a quorum of only a majority of the Voting Members will be necessary, or a written consultation will be carried out to take the decision, in both cases according to the modalities (notice, agenda) defined above.

If a Technical Committee meeting is unable to take decisions because the quorum is not achieved, then decisions may be referred by its Chairman to the Governing Committee, to a second Technical Committee meeting (with unchanged quorum rules) or to a written consultation.

For any modification of the Advantage Compensation Payment (amount, mechanism), a decision can only be taken by a vote of all of Initial Members which are still Members at the time.

## VII) Lead Company

At the date of Entry into Force and unless replaced as specified in § VI, the Lead Company is:  
**FMC Foret SA.**

The Lead Company may resign from its responsibility upon written notice to the Governing Committee with a notice period of six months. Such resignation, however, is only admissible if not endangering the Purpose of the Consortium. The Lead Company shall as far as is reasonably feasible fully and timely comply, on behalf of Members of the Consortium, with the relevant provisions of REACH.

The Lead Company, with the assistance of the Secretariat and other Members, shall where appropriate prepare and submit to the Agency, on behalf of the Members and in the format specified by the Agency, the Registration Dossier, Core Data, Chemical safety Report and Guidance on safe use as necessary for Registration of the Substance, at least two months before the deadline for Registration applicable to the Member(s) within the highest tonnage band.

The Lead Company shall pay its fee as invoiced by the Agency after submission of the Core Data without undue delay. The Lead Company shall further communicate the Registration number as obtained by the Agency after payment of the fee to the other Members without undue delay.

The Lead Company undertakes to inform the Members regularly on the developments of the Registration process. In addition, the Lead Company shall forward in writing to the Secretariat, within 10 calendar days, any communication received either from the Agency or a Member State or any other authority regarding the joint submission or Registration Dossier.

The Lead Company shall if required and approved by the Governing Committee, appeal any adverse decisions of the Agency or the Member States relating to the joint submission or Registration Dossier.

It is noted that each Member must nonetheless themselves carry out the Registration submission and other tasks which, by REACH or otherwise, are their own obligation, in particular submit any relevant confidential or specific company information (including as specified in Annexes 1 and 2), submit necessary information concerning Registration Fee payment and ensure payment of their own REACH Agency Fees and other dues.

## VIII) Individual obligations

1. The Members undertake to make all reasonable efforts to ensure the appropriate and timely completion of the Purpose. In particular, each Member shall:

- Observe and comply with the provisions in this Agreement;
- As specified and subject to the conditions in § V.1.1, make available to the Secretariat all available Information relevant for the Purpose;
- Inform the Secretariat and the Lead Company of any relevant contacts with third parties as specified in § V.1.3;
- Critically assess the Information submitted to or generated under this Agreement;
- Allocate human and financial resources as appropriate, and participate in the work of, the Governing and Technical Committees and any Task Forces;
- Fund the agreed work plans and other agreed actions;
- Inform the Secretariat of any significant change with respect to legal status or organisation of the Member or of its Affiliates;

- Keep the Secretariat continuously informed of a responsible contact person for the duration of this Agreement.

2. Each Member is responsible for observing its rights and obligations pursuant to REACH, in as much as these rights and obligations are not observed by the application of this Agreement. This applies, in particular, to information which is to be submitted to the Agency within the Registration Dossier in due time by each Member as well as any Information communicated by the Members to customers, suppliers and other third parties, such as Safety Data Sheets.

## IX) Competition law compliance

The Members acknowledge that any activities carried out under this Agreement have to be carried out in full compliance with EU competition law, in particular but not limited to Articles 81 and 82 EC Treaty as well as any applicable national laws.

The Members explicitly agree to observe Cefic rules and policies regarding competition law and anti-trust, as available from Cefic (the European Chemical Industry Council, avenue E. van Nieuwenhuysse 4, B1160 Bruxelles, Belgium).

In order to ensure compliance with anti-trust and competition law, data which is not publicly available regarding quantities, manufacturing processes, impurities and uses other than the Identified Uses (Annex 2) will be transmitted, if required, in confidentiality to the Secretariat and will be kept by the Secretariat confidential from other Members and other companies potentially concerned, and will be transmitted in confidentiality only to the Agency as required for REACH purposes, or if necessary for technical studies to relevant contracted experts under confidentiality agreements. If no Secretariat is appointed and such confidential and commercial data needs to be collected, then this must be done through an independent organisation designated by the Governing Committee.

Should it become apparent at any time that this Agreement, any provision of this Agreement, or any activity or decision of the Members of the Consortium, can have a potentially restrictive effect on open and fair competition, in breach of any statutory provision, each Member shall take immediate steps to remedy that situation.

## X) Definition of costs and cost allocation

### X. 1) Valuation of Studies

The value of Existing Information shall be determined on the basis of an evaluation of the scientific quality and relevance to the Purpose, in accordance with **Annex 8**.

### X. 2) Cost sharing principles

All costs of Consortium establishment and management, and all costs engaged for the Purpose, in particular in establishing and submitting the Registration Dossier, including developing studies and purchasing access to third party owned information where necessary shall be shared in accordance with **Annex 9**.

## **XI) Administration & Reporting of costs**

1. The Secretariat shall administrate and keep records of all expenses, compensations due, values of Information, budgets and payments and all other financial matters, access rights and related issues, as specified in § VI.7
2. The Secretariat will present regularly, or whenever significant developments occur, a costs overview to the Governing Committee.
3. The Consortium's funds will be managed either in a specific separate and guaranteed bank account or in some other way, to be decided by the Governing Committee, which ensures security and transparency. Where this is reasonably feasible, available funds will be managed to provide interest to the Consortium.
4. The Governing Committee shall base decisions on contributions and payments on the principle that provided data shall be assessed and incurred costs shall be split in a fair, transparent and non discriminatory way.
5. The financial year shall run from 1 January to 31 December of each calendar year. However, the first financial year shall run from the date of Entry into Force until 31<sup>st</sup> December of the same year, but shall take into account all relevant spending and costs incurred prior to the Entry into Force of this Agreement, as indicated in Annex 11.
6. Each year, the Secretariat shall submit to the Governing Committee, for approval, the accounts of the past financial year and the budget for the following year, presented according to recognised accounting procedures.
7. When, for appropriate reasons, the budget agreed by the Governing Committee has to be increased in the course of the financial year, the decision must be taken by the Governing Committee either prior to the changed spending, or as rapidly as possible in the case of urgent and necessary costs.

## **XII) Limitation of liability**

1. The Members shall undertake their Purpose related activities specified hereunder in good faith and according to all applicable laws and regulations, and they shall use all reasonable endeavours to ensure the best possible results based on the evidence, methods and techniques known at the time.
2. Subject to § XII.3 below each Member shall assume liability for the correctness of the Information which he makes available to other Members and that he is authorised to do so. No warranty for acceptance of the Information by the Agency at the dossier evaluation (according to Title VI REACH) is given.
3. The Member who submits Information to other Members will indemnify them in respect of any claims for unauthorised use or breach of the intellectual property rights of any third party relating to that Information which results from its use by the persons and under the conditions under which it was submitted.
4. Except as specifically indicated elsewhere in this Agreement, none of the Members, including the Lead Company, shall be held liable for any direct, indirect or consequential loss or damage incurred by another Member in connection with the activities contemplated in this Agreement, unless caused by gross negligence or wilful misconduct.
5. Each Member shall be liable with respect to third parties within the scope of its responsibility. The other Members of the Consortium shall support to the extent possible and reasonable, any Member against whom a liability claim has been made within the scope of this Agreement by a third party in its defence against such claim. If a third party makes a claim against a Member such that the other Members are jointly responsible or share part responsibility through this Agreement or the activities developed under this Agreement, then this Member may ask the other Members

to share according to their shared responsibilities any resulting legal actions, arbitration, compensation or costs.

6. The Secretariat acts entirely in its capacity as representative of the Members and bears no individual responsibility or liability for its actions taken in this capacity, with the exception of gross negligence or wilful misconduct. In any case the liability of the Secretariat as agreed in the Consortium Management Service Agreement with the Secretariat will not be overruled by this agreement.
7. Except for gross negligence and wilful misconduct, the Lead Company shall not be liable, to the greatest extent possible under the laws of the relevant jurisdiction, for any direct, indirect, incidental, special, consequential or punitive damages, or any other damages whatsoever arising in connection with the performance of its obligations defined above.

## **XIII) Duration, termination, modification**

1. This Agreement shall be applicable and valid as from the date of Entry into Force. The Consortium shall be formed for the duration necessary to achieve the Registration of the Substance and for as long as this Registration remains valid, unless it is dissolved by a decision of the Governing Committee as defined in § VI.10.
2. This Article and the provisions relating to the protection of confidentiality (§ IV), ownership and use of Information (§ V), dispute resolution and applicable law (§ XIV) and limitation of the liability (§ XII) shall survive the termination of this Agreement. In particular all Confidential Information, and in particular Study reports, Study summaries and robust Study summaries, should be kept confidential indefinitely, that is without limits of time other than limits fixed by applicable copyright law, by REACH or by other applicable contracts or legislations
3. Upon termination of the Consortium and after payment of all obligations of any kind to or by the Members and other parties, the Governing Committee shall decide on the method of liquidation and the distribution of the Consortium's remaining funds. Before dissolution or termination of the Consortium all remaining joint and severable rights and obligations of the Members resulting from this Agreement shall be settled.
4. Amendments to this Agreement must be decided as specified in § VI and must be in written form to be effective.

## **XIV) Dispute resolution and applicable law**

1. The Members shall first attempt to settle amicably any dispute arising out of this Agreement.  
  
If differences remain, each Member shall have the right to submit its observations in writing to the Governing Committee, which shall have to reply in writing stating the reasons for the decision within 2 months.  
  
Should such amicable settlement fail, the dispute shall be resolved by arbitration, ousting jurisdiction by ordinary courts, by a panel of three arbitrators. Each party to the dispute will nominate one arbitrator. These two arbitrators will then designate a third arbitrator who will also act as chairman. The arbitration decision shall be binding on the parties. The arbitration rules of the ICC shall be applicable. The place of any hearing shall be Brussels and the language of the arbitration shall be English.
2. This Agreement shall be governed by the laws of Belgium.
3. If at any time any provision of this Agreement is or becomes invalid or illegal in any respect, this shall have no effect on the validity of the remaining contractual provisions. The invalid provisions are to be replaced, backdated to the time of their becoming ineffective, by provisions which come closest to achieving their objective.



4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.

## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the date of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):

For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director,

Signature:  
on (date of signature)

For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):

Signature:  
on (date of signature):

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):

For and on behalf of **Thermphos International BV**, Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruiter, Director,

Signature:  
on (date of signature)

4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.


## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the date of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):



**ReachCentrum**  
Avenue E. van Nieuwenhuysse 6  
BE - 1160 Brussels  
VAT number: BE 0882 099 291  
Tel: +32 2 676 74 00  
Fax: +32 2 676 74 99  
www.reachcentrum.eu

For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director

Signature:  
on (date of signature)

For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):


Signature:  
on (date of signature):

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):



For and on behalf of **Thermphos International BV**, Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruiter, Director,

Signature:  
on (date of signature)



4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.


## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the data of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):



**ReachCentrum**  
Avenue E. van Nieuwenhuysse 6  
BE - 1160 Brussels  
VAT number: BE 0882 099 291  
Tel: +32 2 676 74 00  
Fax: +32 2 676 74 99  
www.reachcentrum.eu

For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director

Signature:  
on (date of signature):

For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):

 11.04.2008

Signature:  
on (date of signature):

 11.04.2008

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):

For and on behalf of **Thermphos International BV**, Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruiter, Director,

Signature:  
on (date of signature):



4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.


## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the date of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):



**ReachCentrum**  
Avenue E. van Nieuwenhuysse 6  
BE - 1160 Brussels  
VAT number: BE 0882 099 295  
Tel: +32 2 676 74 00  
Fax: +32 2 676 74 99  
www.reachcentrum.eu

For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):

Signature:  
on (date of signature):

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):

For and on behalf of **Thermphos International BV**,  
Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruiter, Director,

Signature:  
on (date of signature):



4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.


## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the date of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):





**ReachCentrum**  
Avenue E. van Nieuwenhuysse 6  
BE - 1160 Brussels  
VAT number: BE 0882 099 291  
Tel: +32 2 676 74 00  
Fax: +32 2 676 74 99  
www.reachcentrum.eu

For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director,

Signature:  
on (date of signature):

22 Apr 08

 Roberto Wurst, Director of **BW BERAPHOS**  
on 16 April 2008 

For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):

Signature:  
on (date of signature):

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):

For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):

For and on behalf of **Thermphos International BV**,  
Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruyter, Director,

Signature:  
on (date of signature)



4. This Agreement constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the Members with respect to the subject matter hereof.


## XV) Signatures

This Agreement has been made in as many originals as signatories below, each signatory below receiving one copy.

This Agreement is endorsed by ReachCentrum as far as its involvement is concerned and ReachCentrum hereby confirms that it will fulfil the role as the Secretariat. The Members by the signature of the present designate ReachCentrum as the Secretariat from the date of Entry into Force of this Agreement and as until decided otherwise by the Governing Committee.

For and on behalf of **REACH Centrum**, Avenue E. van Nieuwenhuysse 6, 1160 Brussels, Belgium, Mr Alain Perroy

Signature:  
on (date of signature):



For and on behalf of **BK Giulini GmbH**, Ytzhak Peretz, Managing Director,

Signature:  
on (date of signature)


For and on behalf of **Chemische Fabrik Budenheim**, Mr Christian Kohlpaintner, CEO and Chairman of the Board, and Mr Hans-Jürgen Reinheimer, Director Business Line Phosphoric Acid

Signature:  
on (date of signature):

Signature:  
on (date of signature):

For and on behalf of **FMC Foret S.A.**, Javier Carratalá, Managing Director,

Signature:  
on (date of signature):



For and on behalf of **Prayon SA**, Mr Willy Marlier, Chief Executive Officer and Mr Jean Braham, Phosphates Direction President

Signature:  
on (date of signature):

For and on behalf of **Thermphos International BV**, Mr. Joachim Koppers, Business Unit Director and Dr. Rob de Ruitter, Director,

Signature:  
on (date of signature)



W

# Annex 1 - Substance identification

## 1. The Substance

**The Substance covered by this Agreement is: Sodium tripolyphosphate**

The following (A, B and C) are considered to be ONE substance for REACH Registration purposes, and to be covered by this Agreement and in particular by the REACH Registration Dossier which will be developed within this Agreement.


**A]** The standard CAS Number for the Substance:

CAS Number: 7758-29-4

EINECS Number: 231-838-7

Also known as: Pentasodium triphosphate, or Triphosphoric acid, pentasodium salt, or Pentasodium triphosphate.

$\text{Na}_5\text{P}_3\text{O}_{10}$



**B]** The following is also considered, for REACH purposes, to be the same substance:

CAS Number: 13573-18-7

EINECS Number: 237-004-9

$\text{H}_5\text{P}_3\text{O}_{10}\text{Na}_x$  – where x is approximately 5 ( $4.5 < x < 5.5$ )

**C]** Conform to Annex 1 of REACH, the Registration of the above will also cover the **hydrate form** of the Substance below:

CAS Number: 15091-98-2

EINECS Number: not applicable

Also known as: Sodium tripolyphosphate hexahydrate.

$6\text{H}_2\text{O}\cdot\text{Na}_5\text{P}_3\text{O}_{10}$

## 2. Impurities:

This agreement covers Registration of the Substance. Impurities depend on production processes, and will be declared, where required, separately and independently by each Registrant, directly or confidentially via the Secretariat, for their own products.

# Annex 2 – Identified Uses

## 1. Non confidential uses

This Agreement covers (as “**Identified Uses**”) all the following non-confidential uses of the Substance, which are to be included in the Registration activities, and in particular in the Chemical Safety Assessment, developed within this Agreement.

NOTE: where relevant this Agreement covers only the REACH requirements for which the Substance is not exempted because of coverage under other regulations: human food additive, medical, animal feed, pharmaceutical, cosmetics, other uses covered by these uses.

- a) detergent uses:
  - domestic, institutional and industrial detergents and cleaners,
  - laundry, dishwasher and other detergents ;
- b) uses in industrial and manufacturing processes, in particular in the following industries and processes:
  - use in construction materials
  - use in ceramics manufacture
  - metal and surface treatment
  - leather manufacture (tannery)
  - textiles processing industries
  - manufacture of paints, varnishes, coatings, printing inks, mastics, etc
  - chemical industry
- c) uses in water treatment
  - addition to drinking water (mains supply, localised treatment ...)
  - treatment of waste water (flocculation)
  - addition to closed process water circuits (for example domestic or institutional boiler/heating circuits, cooling waters, industrial process waters ...)
- d) uses in cosmetics
  - stabiliser for toothpastes
  - stabiliser in other cosmetics uses

See note above, these uses are excluded from Title IV of REACH only (supply chain information) because covered by the Cosmetics Directive 76/768/EC.
- e) uses in human foods, animal feeds, medical and pharmaceutical products: see note above, excluded from REACH implementation by REACH (Art. 2).



## **2. Confidential uses**

Where a use is considered “confidential”, then this use will NOT be covered by the Chemical Safety Assessment, and the Member will be responsible for itself carrying out Registration, Information and documentation requirements for this “confidential” use.

## **3. Identification of “confidential” uses**

The process of identifying uses considered “non-confidential” (Identified Uses) will be as follows:

- a Member wishing to include an use in the Identified Uses covered by this Agreement, beyond those already listed, will indicate this use in confidentiality to the Secretariat;
- the Secretariat will ask all Members whether they object to the addition of this use, without indicating which company requested the addition;
- all Members will reply in confidentiality to the Secretariat;
- if none of the Members objects within 21 days, then the Secretariat will inform the Members that this use is added to the list of Identified Uses; if one or more Members objects then the use will not be added to the list and the Secretariat will inform all Members of this decision, without indicating how many or which Members objected.

Such changes to the list of Identified Uses will be immediately effective as the information by the Secretariat to the Members and will be ratified by decision of the Governing Committee at its next meeting.

## **Annex 3 – Not applicable - company information**

*Names, addresses, representatives and tonnage bands of Consortium Members*

*This information is already given in the text of the agreement*

## Annex 4 – Affiliates of Members

This list indicates the Members' Affiliates as at the date of Entry into Force of this Agreement. This list may evolve as ownership of legal entities is modified in the future.

Members will notify the Secretariat whenever changes in ownership result in a modification of this list of Affiliates, indicating which legal entities should be added to or removed from this list of Affiliates (and providing legal name, address and registration numbers, and any relevant indications regarding Registration Band tonnage changes) but without providing any information about % share ownership or other confidential data.

Changes to this list of Affiliates will be immediately effective as of receipt of notification by the Secretariat and will be ratified by decision of the Governing Committee at its next meeting.

In order to have the Registration Dossier submitted by the Lead Company on behalf of their Affiliates, the Member concerned notifies the names and addresses of its Affiliates to the Secretariat in writing at least thirty (30) days before submission, so the Lead Company is able to include their names and addresses as required in Annex VI Section 1.2 of the REACH Regulation.

### **Thermphos International BV:**

Omnisal GmbH  
Dessauer Strasse 128  
D-06886 Lutherstadt Wittenberg  
Germany

Thermphos UK Ltd.  
Trinity Street, Oldbury  
West Midlands, B69 4LA UK  
United Kingdom

**FMC Foret SA, BK Giulini GmbH, Chemische Fabrik Budenheim KG, Prayon SA:** No Affiliates

## Annex 5 – Existing Studies

List of Existing Studies provided by Members as at the date of Entry into Force of this Agreement, with value as established according to the principles of Annex 8. This list is not necessarily complete and exclusive, that is Members may provide further Existing Information (not included in this list) during the development and submission of the Substance Registration, and this will be evaluated as specified in Annex 8.

“Key study” indicates a study considered as the “key study” as defined in the Agency “Guidance for the Implementation of Reach, Guidance on Data Sharing, September 2007”, as referred in Annex 8.

The Studies in the column “Study owner: CEEP” in the table below were funded by the members of CEEP (Centre Européen d’Etudes des Polyphosphates, a Sector Group of Cefic - the European Chemical Industry Council) and are property of CEEP. The signature of this Agreement by the CEEP member companies who are also the Initial Members of the Consortium constitutes the decision by CEEP to authorise the use of these studies for REACH Registration of the Substance only for all Members and all companies purchasing access rights to the Registration Dossier, according to the conditions specified in this Agreement, subject to payment to the Initial Members (on a one Member – one equal share basis) of the value indicated below (calculated according to Annex 8).

The Members have access to the Studies in the column “Study owner: Nilefos” for use for Registration of the Substance by letter signed by the study owner

Consortium file n°	Key study	Notes	REACH endpoint number [Fleischer reference n°]	Study owner				Klimisch category	Fleischer 2007 average price (all labs) €	Risk and administrative costs	Value with risk, admin. costs, Klimisch correction	Value for Information owner (5)	Value included in Pro Rata Costs (6)
				FMC Foret	Thermphos	Nilefos	CEEP						
			<b>8.1.1 In vivo skin irritation [vi 6.1.1]</b>					1 194 €					
F3	X		“Sodium tripolyphosphate technical: primary skin irritation study in rabbits”, Feb. 17 <sup>th</sup> 1989, Freeman C., FMC Toxicology Laboratory (1989) Unpublished company report. FMC study No. I88-1047.	X				1	145%	1 731 €	866 €	<b>866 €</b>	
C2			Report – a primary dermal irritation study of MCTR-5-75 on abraded and nonabraded skin of New Zealand albino rabbits”, Becker J., Parke G. St. E., Cannon Laboratories Inc. for Mobil Chemical Company, New Jersey (7 <sup>th</sup> May 1975a) Unpublished company report. Study M52-75 Lab. N° SE-6600		X			3	145%	433 €	216 €		
			<b>8.2.1 In vivo eye irritation [vi 6.2.1]</b>					1 343 €					
F2	X		“Preliminary eye irritation of Sodium Tripolyphosphate in rabbits”, signed off June 23 <sup>rd</sup> 1986, W. Barta, T. Cascieri, Unpublished company report. FMC study No. I86-917. ESE No. 3903027	X				1	145%	1 947 €	974 €	<b>974 €</b>	
C1			“Report – the effects of MCTR-5-75 on the eye mucosa of New Zealand albino		X			3	145%	487 €	243 €		

			rabbits", Becker J., Parke G. St. E., Cannon Laboratories Inc. for Mobil Chemical Company, New Jersey (2 <sup>nd</sup> May 1975a) Unpublished company report. Study M51-75 Lab. N° SE-6590											
			<b>Studies covering both of the above endpoints</b>											
H1		1	"Natriumtripolyphosphat toxikologische prüfung" (Skin and eye irritation), Weigand M., Fabwerke Hoechst AG (12 <sup>th</sup> May 1966) Unpublished company report. Study 93/66. Translation 2002 by Roth T., Clariant.	X			3		145%	920 €	460 €			
			<b>8.5.1 Acute toxicity, oral [vi 6.5.1]</b>							1 474 €				
F4	X		"Acute oral toxicity study in rats", August 13 <sup>th</sup> 1997, Watt B., FMC Corporation (1997). Unpublished company report. FMC study No. I97-2169.	X			1		145%	2 137 €	1 069 €		<b>1 069 €</b>	
			<b>8.5.2 Acute toxicity, inhalation [vi 6.5.2]</b>							11 734 €				
F5	X		"Acute inhalation toxicity study in rats, 4-hour exposure", completed September 27 <sup>th</sup> 1988, Jackson G.C., Hardy C.J., Chanter D.O., FMC (1990) Unpublished company report. Sodium tripolyphosphate acute inhalation toxicity study in rats (4-hour exposure). FMC study No. I88-1011.	X			1		145%	17 014 €	8 507 €		<b>8 507 €</b>	
			<b>9.1.1 Short term acute toxicity daphnia [v 7.1.1]</b>							3 472 €				
F1	X		Vaishnav 1991: "Sodium tripolyphosphate: acute toxicity to the water flea (Daphnia magna) under static conditions", February 18 <sup>th</sup> 1991, Vaishnav D.D., Yurk J.J., Ives and Wade B.A., Environmental Science and Engineering Inc, Gainesvill, FL (1991) Unpublished company report. FMC study No. I89-10184. ESE No. 3903027	X			1		145%	5 034 €	2 517 €		<b>2 517 €</b>	
		3,4	INERIS, "Inhibition of the mobility of Ceriodaphnia dubia, test item: sodium tripolyphosphate", Study 50840b, March 2004, and INERIS, "Inhibition of the mobility of Daphnia magna, method OECD Guideline 202, test item: sodium tripolyphosphate", Study 50840a, March 2004			X	1			9 469 €	115%	10 889 €	5 445 €	
			<b>8.5.3 Acute toxicity, dermal route [vi 6.5.3]</b>							2 011 €				
S1	X	1,2	Stauffer Chemical Company Western Research Center, May 13 <sup>th</sup> 1971, Toxicology Lab Report T-1715 "Sodium Tripolyphosphate: to evaluate the acute oral and dermal toxicity, and the skin and eye irritation properties ..."	X			2		145%	6 986 €	3 493 €		<b>1 166 €</b>	
			Also covers endpoints above: acute oral, skin irritation, acute eye irritation											
			<b>9.1.3 Short term acute toxicity fish [v 7.1.3]</b>							4 193 €				
R2	X*	1,2	Dion, 28th October 1985, Rhône-Poulenc "Etude de la toxicité aquatique du tripolyphosphate de soude", Acute aquatic toxicity daphnia and zebra fish, n° 614.9246		X		1		145%	11 114 €	5 557 €		<b>3 040 €</b>	
			Also covers endpoints above: acute toxicity daphnia											
			<b>Growth inhibition of algae [v 7.1.2]</b>							3 472 €				
R1	X		Herschke & Cellier, 28th October 1985, Rhône Poulenc Ecotoxicologie du tripolyphosphate de sodium et du nitrilotriactétate de sodium, mesure de l'écotoxicité des produits vis-à-vis des algues d'eau douce et d'eau de mer" (growth inhibition), n° 614-9240		X		3		145%	1 259 €	629 €		<b>629 €</b>	
			<b>Specific endpoint: eutrophication</b>											
	X	3,4	INIA study "Development of an European Quantitative Eutrophication Risk Assessment of Polyphosphates in Detergents": development of methodology, model, applications, and final study report (M. de Madariaga et al.) April 2007			X	1			169 309 €	115%	194 705 €	97 353 €	<b>97 353 €</b>
			<b>Exposure assessment development and literature search and analysis</b>											

		4	HERA study on STPP: Human & Environmental Risk Assessment on ingredients of European household cleaning products), June 2003, 58 pages, prepared by Rhodia Ecotox for CEEP. Real cost : 13 000 € HERA plus 17 940 € Rhodia Ecotox = 30 940 €			X	NA	30 940 €	NA	NA	NA	
--	--	---	--	--	--	---	----	----------	----	----	----	--

Notes

- 1 Value calculated on basis of SUM of cost for studies for ALL endpoints
- 2 Key study for one endpoint ONLY
- 3 Administration surcharge only counted, not risk surcharge
- 4 Real cost, not Fleisher average
- 5 The "Value for Information owner" includes values for contributions to endpoints where a study is NOT the Key Study
- 6 The "Value included in Pro Rata Costs" includes only the value related to endpoints where the study IS the Key Study

<b>TOTAL</b>	<b>116 121 €</b>
--------------	------------------

## Annex 6 – Specified external experts

The following third parties will have access to the Confidential Information under the same conditions as the Members as defined in section IV:

- 1) CEFIC, avenue E van Nieuwenhuysse 4 bte 2, B 1160 Bruxelles – Belgium
- 2) Mr Christopher Thornton, consultant, TECC Sarl, 27 impasse de Charges, 38300 Bourgoin Jallieu, France
- 3) The Secretariat, as appointed.

## Annex 7 – Typical current costs of Studies and tests

The costs for Studies and tests as given for “average price – all labs” in Fleischer (2007, as below) are used as the basis for the “basic cost” (ex-VAT) valuation for Studies as defined and used in **Annex 8**.

It is noted that these costs will be updated where appropriate to take into account inflation or evidence of general evolution of relevant study prices over time.

Reference is to: M. Fleischer (2007), J. Business Chem., Vol. 4, Issue 3, p. 96-114

*For information only: this article was at the date of Entry into Force available for download at [http://www.wirtschaftschemie.de/journal/2007\\_iss3\\_96-114.pdf](http://www.wirtschaftschemie.de/journal/2007_iss3_96-114.pdf)*

## Annex 8 – Valuation and access to information

The following rules will generally apply for the valuation of the Information i) contributed by Members or third parties, or ii) generated or established by activities under this Agreement by the Consortium, which together with the aforementioned Information are made available to Members or to third parties.

The aforementioned reports are initially evaluated with respect to their scientific value. In a second step, their financial value is calculated as described below.

The object of the valuation is to ensure that adequate compensation is paid to the report owner for the provision of preliminary services and that the recipients' requirement for a high quality report is satisfied.

### **1. Scientific evaluation**

For reports, which are contributed by individual Members, the supplier provides the Consortium with the report itself and available summaries in the form of an IUCLID data set and a robust summary. The robust summary may also be integrated into the IUCLID data set.

The quality of the reports is determined by the Technical Committee, or experts commissioned by the latter, in accordance with the Klimisch et al.<sup>1</sup> method by classifying the report into one of the following categories: (1) reliable without restriction, (2) reliable with restrictions, (3) not reliable, (4) not assignable.

The allocation to the four categories must be accompanied by appropriate substantiation in accordance with the requirements described in the chapter "Documentation of reliability categories in data sheets (IUCLID)" of the Klimisch et al. publication.

The quality of the robust summaries and IUCLID datasets is determined by the Technical Committee, or experts commissioned by the latter.

If the documents (IUCLID data set and/or robust summary) submitted by a party supplying a report are not in conformity with the state of the art or missing, the Technical Committee or experts commissioned by the latter, should develop a robust summary and an IUCLID update.

Also studies, for which no standard protocol exists, e.g., exposure studies, must be documented by an IUCLID data set and a robust summary, and are also to be evaluated under the Klimisch et al. method.

For data, Studies and reports, which are not supported by any standard test protocols or for which a market price is not applicable, the party supplying should provide a document justifying the costs, including the expenses and/or the time required (overview of the process steps, working days, costs per working day), including: development of study concept, exploratory studies, carrying out of the study, analyses, expenses for further contractors, administrative costs (see below).

---

<sup>1</sup> H.-J. Klimisch, M. Andreae, and U. Tillmann, A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data, Regulatory Toxicology and Pharmacology 25, 1-5 (1997)

## **2. Calculation of value**

1) The **basic cost “BC”** of the Study or report is assessed as follows:

- in general, for standard tests and Studies, by referring to the present-day cost of such a study, by reference to the list of typical study costs in Annex 7, updated to take into account inflation and developments in study prices.
- for non-standard tests and Studies and reports, or where it can be demonstrated that a specific non-standard cost is applicable, either the real price of the work (updated by inflation) or a justified estimate of current day costs, will be used, as indicated above.

2) The above value of the Study will then be adjusted according to its **Klimisch category evaluation**, by multiplying  $K \times BC$ , where:

- $K = 100\%$  for Klimisch category 1
- $K = 80\%$  for Klimisch category 2
- $K = 25\%$  for Klimisch category 3
- $K = 25\%$  for Klimisch category 4

3) **Administrative and risk costs:**

- In general, the following fixed surcharges will be added to the cost
  - +30% to cover **risk** inherent in carrying out new Studies: the decision to conduct a Study involves the risk that the Study results could adversely affect or prevent future substance marketing; hence, the Member contributing a report to the consortium was exposed to the risk that the investments made in the Study are of minor or no benefit; the other Members, new parties or parties wishing to acquire a specific Study are not exposed to this risk since they already know the Study result; and
  - +15% to cover **management and administrative costs (choosing and briefing laboratory, managing contracts and payments)**
  - these two % are applied independently, and not additively, to the study cost (in general, total of +45%)
- In particular cases, where it can be justified (specific risks, proof of real costs), different figures may be applied

4) % of value depending on **authorised uses**. The value calculated above will be multiplied by the following factor:

- 50%, corresponding to authorisation to use for REACH Registration of the Substance only for all Members and all companies purchasing access rights to the Registration Dossier, as specified in this Agreement, for Studies made available to the Consortium as specified under § V.1

5) **Calculation if several studies are available** covering the same endpoint:

- In general, calculation of cost shares due by the different Members will be carried out by referring to the indications and examples in the Agency document “Guidance for the Implementation of Reach, Guidance on Data Sharing, September 2007”
- **In all cases, payment will only be considered due by the Consortium for Information which is necessary for the REACH Registration Dossier for the Substance.** That is, if Studies or Information are already available, adequate for Registration of the Substance, and to which the Consortium has access for use in the Registration Dossier (existing studies already provided by existing Members, studies developed by the Consortium, publicly available Information, Information for which the Consortium has already paid for access rights from a third party ...), then the Consortium will **not pay to access further Studies or Information**, unless specifically required to ensure the validity of the Registration Dossier.



- In the above case, a New Member owning additional Information, may nonetheless subtract from the total consortium costs on which their Pro Rata Share is calculated (Z in Annex 9.5B) the value of this Information or the value of the relevant existing information already available (whichever is the lower figure) as indicated in the Agency Guidance referred above
- Where several Existing Studies are available for the same endpoint, as listed in Annex 5, then the Key Study for each endpoint will be identified and the Pro Rata Share due by each Member calculated, according to the examples in the Agency Guidance document referred above, as follows:
  - only the value of the Key Study will be taken into account in calculating the Pro Rata Share
  - Members owning other Information concerning the relevant endpoint may subtract from their Pro Rata Share the calculated value of this information or the value of the Key Study (whichever figure is the lowest)

### **3. Indicative summary table: Rules of access**

This summary table is indicative only, the text of the Consortium Agreement and its Annexes fixes the precise rules concerning rights and ownership of information.

	<b>Member</b>	<b>Company purchasing access to the Registration Dossier or to Information contained therein for REACH Registration of the Substance</b>	<b>Company purchasing access to the Dossier or parts thereof for other purposes</b>
<b>Information developed within this Agreement</b>	<p>Joint owner.</p> <p>Receives full copy of Registration Dossier and also copies of full study reports, etc.</p> <p>Use for any regulatory purpose for the Member or its Affiliates</p> <p>Rights may not be sold or transferred.</p>	<p>Receives full copy of Registration Dossier.</p> <p>Does not receive copy of study reports, summaries or other data.</p> <p>Use for REACH Registration of the Substance only</p>	<p>To be negotiated with the Secretariat and decided by the Governing Committee on a case by case basis</p>
<b>Information owned by Members</b>	<p>Use for REACH Registration of the Substance only.</p> <p>Does not receive copy of study reports, summaries or other data, except as included in the Registration Dossier.</p>		<p>To be negotiated directly with the Information owner (unless a mandate for negotiation has been given to the Secretariat)</p>
<b>Information owned by third parties referred in the Registration Dossier</b>	<p>Use for REACH Registration of the Substance only.</p> <p>No other rights unless explicitly transferred by the Information owner</p>		

# Annex 9 – Financial rules

## 1a. General financial rules

The fees and amounts below are contributions fixed as defined, intended to cover the approximate relevant costs in a simple, fair and reasonable manner, and not to correspond to the exact amounts.

All figures indicated are exclusive of VAT and of any other taxes which may be due.

In all cases, no rights of access to the Registration Dossier or to any other Information can be claimed by a new Member or by a party purchasing access rights, until :

- all payments due have been effectively received by the Secretariat;
- the recipient has accepted, by written signature, agreement to the conditions of access. These conditions will either be as specified by the full text of this Agreement and its Annexes, or will be decided as defined in § VI based on this Agreement and its Annexes.

In all cases, the payments indicated cover access, as specified, to the Registration Dossier and/or Information as these stand only, and with no guarantee of their validity or acceptance by the Agency. In particular, if after the Date of Registration, the Agency requests further testing of the Substance or for other reasons it becomes necessary to develop or supply further Information to support the Registration of the Substance, then the Members are not obliged to bear these costs and are not obliged to carry out the required work, unless they decide to do so through the Consortium or otherwise. Such further work and costs may be shared between all parties who choose to continue to support the Registration or the work organised in other ways to be defined.

In all cases, the payments indicated below are due per company manufacturing, importing or representing the Substance:

- one company's payment will cover its Affiliates as defined in this Agreement;
- payment by an Only Representative of more than one company will be calculated per company, according to the number of companies represented (unless these are Affiliates as covered above);
- Only Representatives will therefore be required to specify and justify the number of companies manufacturing STPP (other than Affiliates) effectively being represented, either by listing these companies or in case of confidentiality or anti-trust issues, by depositing the list with a lawyer or other recognised party who will transmit only the number.

A) **Access for REACH Registration of the Substance: *three different possibilities*** are open to any non-Member EU wishing to refer to the Registration Dossier or part thereof, for Registration of the Substance:

- to become a Member of the Consortium, subject to respecting the Membership criteria and being accepted as a Member according to the procedures in this Agreement. This results in the rights, as specified in this Agreement for all Members, to refer to this Registration Dossier for REACH Registration of the Substance. In this case the new Member must pay **three amounts: the Advantage Compensation Payment, the Pro Rata Share, and also the Consortium Entry Fee** as defined below, and will obtain a Letter of Access as per the model in Annex 10A;
- to purchase access to the **full** Registration Dossier developed by the Consortium without becoming a Member of the Consortium. In this case, the third party must pay **two amounts: the Advantage Compensation Payment and the Dossier Costs Contribution** as defined below (but NOT the Consortium Entry Fee), and will obtain a Letter of Access as per the model in Annex 10B;
- to purchase access to **part of** the Registration Dossier developed by the Consortium without becoming a Member of the Consortium. In this case, the third party must pay a **part** (proportional to the Information access requested) of these two amounts and will obtain a Letter of Access as per the model in Annex 10B, appropriately modified to limit access to relevant parts of the Information.

B) **Access for REACH Registration of other substances or for other purposes:** Third parties (that is non-Members) wishing to purchase access to the whole or part of the Registration Dossier developed by the Consortium for purposes other than REACH Registration of the Substance (other regulatory purposes, read-across for REACH Registration of other substances, etc), will generally be required:

- 1) for access to Information, Studies or reports owned by third parties to which the Consortium does NOT have ownership and does not have the right to sell or transfer access: access must be directly negotiated with, Letter of Access and other documents signed with and payments made to the relevant owner;
- 2) for Information, Studies or reports referred in the Substance Registration Dossier and (a) owned by Members, or (b) developed by the Consortium under this Agreement, or (c) owned by third parties and for which the Consortium has the right to negotiate third party access under the terms of this Agreement: access conditions and cost will be negotiated with the Secretariat as a function of the elements for which access is required and of the intended uses, and will be decided by the Governing Committee as specified in § VI.

## **1b. Indicative summary table : Payments due for Membership and/or Dossier access**

This summary table is indicative only, the text above and below it fixes the precise financial rules.

	<b>Advantage Compensation Payment</b>	<b>Consortium Entry Fee</b>	<b>Pro Rata Share</b>	<b>Dossier Contribution Costs</b>
<b><u>New Members</u></b>				
	<i>Shared equally between Initial Members only</i>	<i>Shared equally between existing Members</i>	<i>Effectively reduces the share of cost for existing Members</i>	<i>Shared equally between existing Members</i>
- first new Member	20 000 €	20 000 €	Costs x 1/(N+1)	
- second new Member			Costs x 1/(N+2)	
- etc			Costs x 1/(N+etc.)	
<b><u>Companies wishing to refer to the full Registration Dossier for REACH Registration of the Substance (not becoming Members)</u></b>				
- first company	20 000 €	NOT applicable		Costs x 1/(N+1)
- second company				
- etc				
	<i>Corresponds to the goodwill, experience and know-how of 30 years' cooperation between the Initial Members in CEEP</i>	<i>Corresponds to the risk engaged by the Members of the Consortium in initiating and leading the Registration Dossier development.</i>	<i>Corresponds to fair shares of the Registration Dossier and Consortium costs.</i>	
<b><u>Company wishing to refer to part of the Registration Dossier for REACH Registration of the Substance</u></b>				
	Part of 20 000 € proportional to part of Dossier required	NOT applicable		Part of Costs x 1/(N+1), proportional to part of Dossier required
<b><u>Company wishing to refer to all or part of the Registration Dossier for purposes other than REACH Registration of the Substance</u></b>				
Access conditions and cost to be negotiated directly with the owners of the Information required, or with the Secretariat if the Information owner has given a mandate to the Secretariat (in this case, subject to Administration Fee for Non Members)				

## **2. Administration Fee**

In the case of (1.B2) above, an Administration Fee of 15% of the final calculated payable value of the Information, as calculated under steps 1-4 of Annex 8, will be collected by the Consortium to cover the costs of secretariat and administration.

This Fee will NOT be charged to companies purchasing access to part of or to the full Registration Dossier under the conditions specified in 1.A above, as it is in this case covered by the other payments indicated in this Annex.

The Administration Fee is retained by the Consortium (the payable value of the Study or data being transferred to its owner).

## **3. Advantage Compensation Payment:**

This is a one-off payment of a fixed amount required for any non-Member wishing (i) to become a Member and/or (ii) to use the REACH Registration Dossier developed by the Consortium for their own REACH Registration of the Substance, and is additional to and independent of the Pro Rata Share, Dossier Contribution Costs and Consortium Entry Fee.

The Advantage Compensation Payment covers the goodwill, experience and know-how resulting from the work together of the Initial Members, and the with competent third parties (consultants, Cefic ...), in joint research and collaboration concerning STPP through the association CEEP (Centre Européen d'Etudes des Polyphosphates, joint industry association established in Belgium over 30 years ago and for the last ten years operating as a CEFIC Sector Group), which have been essential to achieving the establishment of this Consortium and to ensuring conditions appropriate for the timely and effective completion of the Registration Dossier. This includes carrying out the HERA STPP study (2003), see Annex 5, which provided significant starting information for the writing of the Registration Dossier.

The Advantage Compensation Payment and Consortium Entry Fee are not payable by companies who have been members of CEEP in the past, who have as such contributed financially to CEEP's activities over the last five years (2003-2007), and who have participated in the preparation of the Consortium over the period end 2007- early 2008..

This Advantage Compensation Payment is fixed at **20 000 Euros**;

The Advantage Compensation Payment is credited and reimbursed only to those Initial Members which are still Members at the time at which the payment is due (an equal share of sum indicated above to each of these Initial Members) and is not due in any part to new Members having joined the Consortium after the date of Entry into Force.

In the case of a non-Member wishing to use only part of the Registration Dossier for their own REACH Registration of the Substance, then only a fraction of the sum above, defined by the Governing Committee proportional to the Information requested, will be payable.

## **4. Consortium Entry Fee:**

This payment is due by any company which becomes a new Member of the Consortium after the date of Entry into Force (not by Affiliates of Members).

This Fee covers:

- time and staff costs necessary for the existing Members to formally decide upon the request for new Membership according to the decision process specified in this Agreement;
- Secretariat and other Consortium administration costs resulting from the inclusion of the New Member in the Consortium, including modification of the Consortium Agreement, adjusting the accounting system, recalculating the Pro-Rata Share, issuing corresponding invoices and reimbursements;
- the new Member's potential financial benefit resulting from their becoming a Member, because of reimbursements of Pro-Rata Share, Dossier Contribution Costs and Consortium Entry Fee

which will benefit them if in the future another company becomes a new Member of the Consortium or purchases access to the Registration Dossier or to other Information developed by the Consortium.

This Consortium Entry Fee is fixed at **20 000 Euros**.

The amount of this Fee is credited to and reimbursed to (shared equally between) all existing Members

### **5A). Pro Rata Share:**

That is, participation by Members in expenses incurred in establishing and managing the Consortium and in producing, managing and submitting the Registration Dossier, including costs of existing and new Information obtained or developed by the Consortium for the Purpose. Participation is as per the cost sharing mechanism specified below which ensures an equal share of these costs between Initial and new Members.

The Pro Rata Share has the following two elements, as specified below:

- for any newly joining Member, a one-off payment, on joining, to cover the Pro Rata Share of costs engaged by the Consortium up until the date of joining (**past costs**). These costs are the total of the following:
  - > costs engaged during the establishment of the Consortium, that is before the date of Entry into Force of this Agreement, as detailed in Annex 11
  - > costs of Existing Studies provided by the Initial Members, as detailed in Annex 5
  - > costs engaged by the Consortium from the date of its establishment through until the date of joining of the new Member

The amount above of the Pro Rata Share paid by a new Member is credited to (shared equally between) all existing Members, so that after this re-accounting, all Members (existing and new) have in effect paid the same equal share of the total costs.
- for existing Members and for any newly joining Member after joining, the Pro Rata Share of all **future costs** engaged by the Consortium, on a one Member – one share basis.

Payment by a New Member of the Pro Rata Share of past costs is due as for other payments as defined in point 8 of this Annex. For the future costs, payment is subject to the same rules as other Members.

Rules defining how are calculated the Members' costs for their work in the consortium are defined below.

### **5B). Cost sharing mechanism: one Member = one share**

All Consortium costs are shared on a “**one Member – on equal cost share**” basis, that is if the Consortium has N Members then the Pro Rata Share for each Member is 1/Nth of the Consortium costs.

Therefore, if at the date of entry of a new Member into the Consortium:

- the number of Members passes from N to (N+1)
- the Consortium costs engaged up until the date of entry are Z Euros

then

- the new Member must pay [  $Z/(N+1)$  ] Euros for past costs (in addition to the Advantage Compensation Payment)
- each existing Member will be reimbursed [  $Z/(N+1)/N$  ] Euros

and after the date of entry of the new Member, each of the Members will pay an equal share of future costs, that is  $1/(N+1)^{\text{th}}$  part.

However, a Member will only be liable to pay costs relating to Studies required according to the relevant tonnage band, so that if some Members are not concerned (lower tonnage band) by certain Studies, the Pro Rata Share for these Studies for the remaining Members will be higher (division by a smaller number of parts).

### **5C). Costs included in Pro Rata Share costs**

The following will be accounted in the calculation of the Pro Rata Shared costs, by the Secretariat, applying where appropriate the rules on Member costs fixed below:

- Administrative expenses incurred for the management of the Consortium, including the Secretariat, legal and accounting costs, coordination and other administrative costs, management of confidential data or external experts, etc. ;
- Value of or rights of access to (evaluated according to Annex 8) Existing Information owned by Members (as detailed in Annex 5) and purchased from other parties provided that the party needs to submit the Information according to its tonnage band;
- Costs for new Information developed where required for the Purpose and provided that the party needs to submit the Study according to its tonnage band;
- Costs for a party accomplishing tasks assigned to it by the Consortium;
- All other costs engaged conform to this Agreement in order to achieve the Purpose

### **5D). Rules for company costs**

The following rules will be used for evaluating and reimbursing costs engaged by Members in preparing, establishing and managing the Consortium and in contributing to achieving the Purpose. These amounts will be counted as Consortium costs (Pro Rata Share costs as above).

In order to avoid excessively detailed accounting, the following “fixed” costs are taken as the basis for calculating Member input and work.

For participation in a physical meeting:

- two days staff time, per Member, as at rate below, including preparation and travel time,
- travel costs on the basis of an average cost of 500 Euros per Member, including travel costs and booking costs.

For participation in a telephone meeting:

- one day staff time as at rate below, including preparation,
- organisation costs as spent by Secretariat or organisation organising.

Staff time rate:

- 800 Euros per day / 400 Euros per half day, including secretarial and overheads.

The amounts and numbers of staff days indicated above are per Member per meeting at which the Member effectively participates, irrespective of how many persons are in fact present per Member.

## **6. Dossier Contribution Costs:**

This is payable by parties wishing to purchase access to the Registration Dossier developed by the Consortium **without becoming a Member of the Consortium**. The Dossier Contribution Costs correspond to a fair participation in the total expenses (referred to below as “TX”) incurred in establishing and managing the Consortium and in preparing, justifying, writing and submitting the Registration Dossier and fulfilling other Registration requirements.

The Dossier Contribution Costs are calculated in the same way as specified under points 5A – 5D of this Annex for the Pro Rata Cost, and include the same elements, but they are calculated **through to the Date of Registration**.

The Dossier Contribution Cost is calculated as in (5C) above, where N is the number of Members at the date of the Governing Committee decision according access. Thus if the total expenses defined above are TX, then the Dossier Contribution Cost payable is  $[TX/(N+1)]$ .

The Dossier Contribution Costs payment is credited to and reimbursed to (shared equally between) all existing Members, so that after this re-accounting, the Members at the date of access purchase and the party X paying the Dossier Contribution Costs have in effect agreed to pay the same equal share of the total costs  $[TX/(N+1)]$ . However, should a further party Y agree later to purchase access to the Registration Dossier developed by the Consortium without becoming a Member of the Consortium, and so pay the Dossier Contribution Costs, then the share paid by the Members will become lower  $[TX/(N+2)$  etc] than that of the parties X and Y  $[TX/(N+1)]$ . This difference is compensated by the Consortium Entrance Fee payable by New Members defined above.

In the case of a non-Member wishing to use only part of the Registration Dossier for their own REACH Registration of the Substance, then only a fraction of the sum above, defined by the Governing Committee proportional to the Information requested, will be payable.

## **7. Financial contributions in case of leaving the Consortium**

All financial contributions are non reimbursable.

In case a Member should leave the Consortium, either on its own decision or by exclusion and for whatever reason, this Member remains liable to pay:

- the Pro Rata Share of all Consortium administration and management costs for the calendar years (1 January to 31 December) prior to the Date of Leaving (see §III.3 and §III.4), for the calendar year of the Date of Leaving, and for the calendar year following this calendar year (through to 31 December of the year after the date of leaving);
- the Pro Rata Share, until the activity is completed, of all Studies, contracts, administrative procedures and other specifically budgeted items of activity engaged prior to the Date of Leaving. The Member leaving thereby acquires a joint ownership of the Information developed under these activities.

## **8. Consortium accounting system and payments**

The Secretariat will establish invoices for payment of all amounts due indicated above. The invoice shall be established rapidly following the relevant decision of the Governing Committee (decision on rights of access, decision on budget and cost sharing ...); the invoice will be accompanied where appropriate with justifications of costs and budgets; payment must be made within 30 days of receiving the invoice. The relevant Letters of Access will be established within 30 days of the Secretariat receiving the payments invoiced.

The Secretariat will maintain a Consortium internal accounting system, where for each Member is credited:

- money spent for the Purpose on Consortium preparation, establishment and management (travel and staff time, as above, and other relevant costs),
- value of Information owned by the Member and made available to the Consortium for the Purpose,
- where relevant, part due for reimbursement to the Member corresponding to its part of CEEP owned Studies or work made available by CEEP to the Consortium for the Purpose,



- money due for relevant shares of Advantage Compensation Payment, Consortium Entrance Fee, Pro Rata Share payment made by a new Member entering, Dossier Contribution Costs payment,
- payments due for Studies or Information owned by the Member and made available, via negotiation through the Secretariat, to third parties or for purposes other than Registration of the Substance,
- other payments due to or from the Member for Consortium activities,
- payments made into or received from Consortium funds.

The Secretariat will also maintain an internal accounting system of all amounts due to and from third parties, both to/from the Consortium and to/from each Member, for access to Information purchased by the Consortium and/or access of third parties to the Registration Dossier (all or part thereof) and/or to Information referred in this Dossier or developed within this Agreement.

The Secretariat will collect funds from Members sufficient to cover expected spending, for a period of 3 months – one year, to be decided by the Governing Committee, in order to minimise administrative costs (reduce number of invoices) whilst avoiding excessive advance collection. Invoices received from the Secretariat must be paid within 30 days of receiving them. Where reimbursements of costs or credits are due to Members, the Secretariat will group these and make payments on the same period basis as for fund collection.

# Annex 10A – Model Letter of Access (for Members)

## Model Letter of Access for Members for the Registration of Sodium Tri Poly Phosphate

By this letter, the Members of the Consortium for the REACH Registration of Sodium Tri Poly Phosphate (hereafter referred to as "the Consortium" and "the Substance") agree that the REACH Registration Dossier, and also all data, studies, summaries, waiving argumentations, reasoning of testing proposals and/or assessments, and other relevant information submitted by the Consortium in support of the Registration under REACH of the Substance may be referred to:

- by **Company XYZ**, which being a Member of the Consortium, and its Affiliates
- in order to support REACH Registration of the Substance

This Letter of Access is subject to and subservient to the terms of the Consortium Agreement signed between the Consortium Members. The rights and obligations resulting from this Letter of Access are as specified in the Consortium Agreement and its Annexes.

"The Consortium" above refers to the Consortium established by signature on in March 2008 of the Consortium Agreement between the following initial Members :

- BK Giulini GmbH
- Budenheim Chemische Fabrik
- FMC Foret SA
- Prayon SA
- Thermphos International BV

Signature: Authorised Representative of the Consortium

# Annex 10B – Model Letter of Access (Non Members)

## Model Letter of Access for Non Member for the registration of Sodium Tri Poly Phosphate under REACH Regulation

By this letter, the Members of the Consortium for the REACH Registration of Sodium Tri Poly Phosphate (STPP), as indicated below, (hereafter referred to as “the Members”, “the Consortium” and “the Substance”), agree that:

- the REACH Registration Dossier, including data, Studies, summaries, waiving argumentations, reasoning of testing proposals and/or assessments owned by Members of the Consortium and submitted by the Consortium in support of the Registration under REACH of the Substance (hereafter referred to as “the Dossier”)

may be referred to:

- by **Company XYZ** (hereafter “The Applicant”)

in order to support

- the Applicant’s Registration of the Substance under REACH

subject to the following conditions:

1. the right to refer is restricted only for the Registration purpose as specified above, that is only for REACH Registration, and only for the Substance;
2. the right of refer is solely granted in favour of the Applicant is not transferable to any other entity or person;
3. the Applicant is not authorised to receive any copies of the Dossier nor is the Applicant authorised to inspect or view the Dossier or any related specific document in whole or in part, only the right to refer to the Dossier and its contents for the purpose specified above is granted;
4. this Letter of Access shall in no event be construed as granting the Applicant any property rights whatsoever in the Dossier or to any information contained within it or elsewhere;
5. the right to refer granted by this Letter of Access is subject to the conditions specified in the Consortium Agreement (including its Annexes), of which the Applicant has received copy / AND/OR / is subject to the specific conditions listed below and annexed to this Letter of Access.

The right to refer is granted subject to the Members receiving the signature in writing by the Applicant of acceptance of these conditions (OR SPECIFY date of this signature).

The right to refer remains subject to the permanent respect of these conditions, and to effective payment of the relevant costs and fees.

“The Consortium” above refers to the Consortium for REACH Registration of STPP, established in 2008 between the following Initial Members : BK Giulini GmbH, Chemische Fabrik Budenheim, FMC Foret SA, Prayon SA, Thermphos International BV

Signature: Authorised Representative of the Consortium

## Annex 11 – Consortium preparatory work costs

Estimated costs of preparatory work, engaged for the preparation and establishment of the Consortium, that is **before Entry into Force** of this Agreement, are outlined below. Exact costs will be justified in the Consortium accounts by invoices and receipts.

The costs below are in addition to Existing Studies, detailed in Annex 5. They will be included in the Pro Rata Share calculations as specified in Annex 9.

All prices below are ex-VAT

### Data gap analysis and complementary assessment – Safepharm – October 2007 – March 2008

Estimative price to be confirmed: GB£ 3,500 = 4,700 €

Tests carried out by Safepharm, launched February 2008

Estimative prices to be confirmed:

- relative density	GB£ 570	= 1,500 €
- skin sensitisation LLNA (mouse)	GB£ 1825	= 2,500 €

### Member company costs:

- Meeting 4<sup>th</sup> September 2007
- Meeting 8<sup>th</sup> November 2007
- Meeting 13<sup>th</sup> December 2007
- Meeting 15<sup>th</sup> January 2008
- Meeting 11<sup>th</sup> March 2008
- - time spent by company personnel preparing Consortium agreement
- - calculation as per rules specified in Annex 9

### Consultant: Christopher Thornton – time spent and costs

- - meetings as above, including coordination, minutes
- - coordinating decision making between the future Consortium members to prepare agreements and launch work
- - preparation Consortium agreement, secretariat contract, other administrative issues
- - defining and overseeing data gap analysis study, call for proposals for Consortium management, preparation of Safepharm studies above
- - purchase of electronic copies of relevant studies (Infotrieve costs)
- - time spent looking for relevant Studies

Time (fees) 2007	= 10,000 €
Time (fees) 2008 first semester	= 15,000 €
Costs (travel, Studies purchase ...) 2007	= 4,572 €
Costs 2008 prior to Entry into Force, estimate	= 2,000 €

### Cefic – time spent and costs

- - participation of Dominique De Halleux in meetings and coordination or Consortium preparation, June 2007 – February 2008
- - meeting room costs and organisation costs for the meetings indicated above



**THIS AGREEMENT IS CONCLUDED BETWEEN:**

**ReachCentrum**, SPRL, N° 0882 099 291 (= VAT / RPM Brussels), having its seat of incorporation at Av E Van Nieuwenhuysse 6, 1160 Brussels, Belgium, represented by Mr Alain Perroy, Director General (HEREINAFTER ReachCentrum)

**AND**

**Companies listed on page 6 of this Agreement** (hereinafter referred to as **COMPANY** or **COMPANIES**),

**HEREINAFTER REFERRED TO INDIVIDUALLY OR COLLECTIVELY AS THE "PARTY" OR THE "PARTIES"**

**WHEREAS**

REACHCENTRUM provides a set of services defined hereunder in order to help companies to meet the requirements laid down by the Regulation of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (hereinafter referred to as "**REACH**"). Among several obligations under REACH companies are required to share data and jointly submit parts of registration dossier for substances manufactured or imported within the European Union.

REACHCENTRUM endeavors to facilitate fulfillment of this obligation by organizing and coordinating the cooperation between COMPANIES within a legal framework of a consortium agreement in full compliance with the requirements of competition law.

REACHCENTRUM offers consortium management services in order to support the companies in a phased approach to prepare and form a REACH consortium ((hereinafter referred to as "**Consortium**") under a separate consortium agreement (hereinafter referred to as "**Consortium Agreement**") and to manage this Consortium to meet the REACH Registration requirements in time (hereinafter referred to as "**Consortium Support Project**").

In order to organize technical support to a Consortium REACHCENTRUM has identified reliable service providers who commit to REACHCENTRUM quality standards as REACHCENTRUM Preferred Suppliers. REACHCENTRUM shall maintain a list of REACHCENTRUM Preferred Suppliers and evaluate the services provided on a regular basis.

REACHCENTRUM has extensive experience of Consortium management and is willing to make it available for the benefit of the COMPANIES. In the course of this activity, REACHCENTRUM may subcontract parts or totality of its services to external consortium managers and upon approval of the COMPANIES commission third parties which have been identified as REACHCENTRUM Preferred Suppliers, in particular research institutes, experts and laboratories, in the name and for the

A handwritten signature in blue ink, appearing to be a stylized 'A' or similar character.



account of the interested COMPANIES to carry out testing, development, research and any other consultancy work relevant in the respective area of endeavor.

## **THE PARTIES HAVE AGREED UPON THE FOLLOWING**

### **Article 1. Purpose**

The COMPANIES hereby entrust to REACHCENTRUM and REACHCENTRUM agrees to use its expertise and provide consortium management services specified in the technical proposal being included as Annex 1 according to the financial conditions described in Annex 2 (hereinafter referred to as "**the Services**").

If any provision in this Agreement conflicts with any provision in the Consortium Agreement as signed by both REACHCENTRUM and by the COMPANIES, then the relevant provision of this Consortium Agreement applies.

### **Article 2. Contracts with third parties**

2.1 In performing the Services referred to in Article 1 of this Agreement REACHCENTRUM reserves the right to sub-contract parts or totality of Services to external consortium managers or other suppliers, who shall be fully bound by the provisions of this Agreement. As specified by the Consortium Agreement, any subcontracting agreement is subject to prior approval of the Governing Committee of the consortium.

2.2 As part of the Services specified in Article 1, REACHCENTRUM upon request and approval of the COMPANIES may sign contracts in the name, on behalf and for account of the interested COMPANIES with third parties, in particular external services providers and laboratories. REACHCENTRUM shall make its best efforts to identify reliable service providers and ensure they timely comply with their contractual obligations. For that purpose REACHCENTRUM shall maintain and develop a list of REACHCENTRUM Preferred Suppliers who commit to REACHCENTRUM quality standards.

2.3 By the present, the COMPANIES agree to the subcontracting of services to Thornton Environment Communication Consultant TECC Sarl, as specified in Annex 4 Agreement..

### **Article 3. Exchange of information between the parties**

3.1 Each COMPANY is obliged to:

- Inform REACHCENTRUM in good time of characteristics of substances or preparations indicating any information relevant for registration purpose;
- Provide in good time all available data, studies and other documentation, in particular substantiated costs for proprietary data and studies, required for the successful handling of this Agreement and fulfillment of registration requirements;
- Inform of any modification of its contact details. In case of a COMPANY's contact details no longer being valid, REACHCENTRUM will not be bound to undertake investigations and any fund will be kept in custody until validly claimed.



3.2 REACHCENTRUM is obliged to report to COMPANIES on the progress of activities undertaken in performance of this Agreement under the conditions specified in Annex 1.

#### **Article 4. Contractual period**

4.1 This Agreement shall be effective from the date of signature by all PARTIES.

4.2 The expiry date of this Agreement shall be effective with the completion of the purpose as defined in Article 1. Prior to that date, the Agreement may be terminated by the mutual agreement between REACHCENTRUM and a 2/3 majority of the COMPANIES. A COMPANY may terminate its own participation in this Agreement if it terminates its participation in the Consortium Agreement provided that it serves one month prior written notice to REACHCENTRUM and provided that it has fulfilled all of its financial obligations to the date of termination.

In this case, the remaining COMPANIES shall confirm their commitment to continue the Consortium Support Project by sending a notice to REACHCENTRUM within fifteen (15) working days. No response shall be regarded as confirmation to continue this Agreement.

4.3 If any PARTY does not fulfil any of its obligations under this Agreement, the other PARTIES are entitled to serve notice upon it by registered mail. If, ten (10) working days after the notice, the defaulting PARTY still does not fulfill all its obligations, the other PARTIES shall have the right to terminate the Agreement with immediate effect by registered mail.

4.4 After termination, for whatever reason and at whatever time, any fees or charge(s) for the work ordered and prepared and costs incurred up to the termination due to REACHCENTRUM shall remain unaffected by the termination: no reimbursement whatsoever shall be due by REACHCENTRUM and any fee or charge due to REACHCENTRUM shall still be due.

#### **Article 5. Payment and invoicing**

5.1 To compensate REACHCENTRUM for costs incurred and to be able to maintain the necessary infrastructure, COMPANIES undertake to pay REACHCENTRUM a provision for the fees per hour for services of the persons indicated in the Annex 1 under the conditions of Annex 2 to this Agreement. The provision will amount 100% of total budget excluding contingency and meeting costs. This provision also includes the estimated costs for work to be done by external service providers as described in Annex 3 and Annex 4.

5.2 All fees shall be shared by the current and future members of the consortium under conditions specified in Consortium Agreement.

5.3 REACHCENTRUM shall invoice COMPANIES for the conducted activities specified in Annex 1 under the conditions of Annex 2 upon signature of this Agreement for documented expenses incurred in performance of this Agreement.

Any additional expenses and any other costs incurred by REACHCENTRUM in performance of this Agreement, including meeting costs and possible travel expenses, will be invoiced on an actual cost basis. Additional travel and accommodation expenses and meeting costs have to be agreed upon in writing before being engaged, which can include e-mail.



ReachCentrum will submit an invoice for the provision at the beginning of the project. At the end of the project an invoice will be prepared based on time actual spent with an equal split of the costs over the COMPANIES.

5.4 Estimated budget indicated in Annex 1 to this Agreement has been calculated on the basis of information supplied by the COMPANIES. If the information is incomplete or the COMPANIES' plans are subsequently amended, leading to an increase in the work required from REACHCENTRUM, REACHCENTRUM reserves the right to increase the budget accordingly, subject to prior written approval of all COMPANIES (decided according to the rules as agreed in the Consortium Agreement for Sodium Tri Poly Phosphate (STPP)), which should not be unreasonably withheld or delayed.

5.5 Costs made by REACHCENTRUM prior to the signature of this Agreement are related only to work to be performed by external service providers like the work described in Annex 3, but will not exceed more than 10% of the provisions as described in Article 5.1.

5.6 Costs made by the Consortium before the Consortium Agreement has been signed by the member companies will be accounted for in the system, subject to the COMPANIES providing a clear list of such expenses, accompanied with appropriate invoices and justification and with necessary information about to whom payment is due.

5.7 All invoices shall be expressed in €, shall be paid within forty five (45) calendar days of receipt of the invoices and are governed by the provisions of the Act of 2 August 2002 on minimizing delays of payment in commercial transactions.

In the event of non-payment by the due date, REACHCENTRUM shall be entitled to charge interest at the rate provided by the aforementioned act and a penalty of 100 €. REACHCENTRUM retains the right to reimbursement of all costs (including reasonable attorney fees) it would have made in order to enforce payment of an unpaid invoice.

5.8 Payment shall be made exclusively to the bank account as defined in Annex 2. Cost, if any, shall be at the charge of the COMPANIES.

#### **Article 6. Confidentiality**

Refer to Article IV of the Consortium Agreement for Sodium Tri Poly Phosphate (STPP).

#### **Article 7. Force majeure**

Any PARTY may terminate this Agreement immediately and without indemnity by serving written notice upon the other in the event that a PARTY suffers an event of *force majeure* which frustrates or prevents substantial performance by that PARTY of its obligations hereunder for a continuous period of 2 months.

#### **Article 8. Jurisdiction and applicable law**

Refer to Article XIV of the Consortium Agreement for Sodium Tri Poly Phosphate (STPP).

#### **Article 9. Liabilities**

9.1 The information, documents and advice provided by REACHCENTRUM to COMPANIES are provided in good faith. REACHCENTRUM endeavours to make its best efforts to up-date regularly the information, but it is not claimed to be either

ReachCentrum SPRL

P-1047/JKW/C007 (29/5/2008)

Turning our REACH expertise into practical help for industry





exhaustive or constituting a unique and sole interpretation of the REACH Regulation and related implementation texts. COMPANIES shall use their sole judgement on how to use and apply the information regarding their products, substances and related services for which REACHCENTRUM shall not incur any responsibility.

9.2 The liability of REACHCENTRUM, its employees' or external consortium managers' referred to in Article 2.1, in the case of violation of obligations and tort shall be limited to intent and gross negligence. In any case, the liability shall be limited to the foreseeable, contractually typical damages, excluding any non-typical or unforeseeable damage or indirect or consequential damages such as (but not limited to) loss of production, revenue or profit. This limitation shall not apply to damages from injury to life, body or health.

REACHCENTRUM shall be held responsible for the services performed to COMPANIES by any third party it may commission in accordance with Article 2.2 as long as the commissioned third party shall remain responsible for his own service. REACHCENTRUM shall not be liable for breaches of contract or defective performance by the third party. REACHCENTRUM will strive to its best ability to choose the reliable third party and monitor the third party to ensure that he meet the agreed timeline, but is not liable for delays caused by the third party, except if the delay is caused by the gross negligence or willful misconduct of ReachCentrum, its employees' or external consortium managers' referred to in Article 2.1. As specified by the Consortium Agreement § XII.6, the liability of ReachCentrum as agreed in the present agreement cannot be overruled by the Consortium Agreement.

REACHCENTRUM shall support the COMPANIES in claims against any third party commissioned in accordance with Article 2.2 to the extent possible and reasonable.

REACHCENTRUM shall not be liable for any damages resulting from any act, omission, error or delay in meeting the agreed timeline made by any of COMPANIES or resulting from any cause beyond REACHCENTRUM's reasonable control.

9.3 Subject to provisions stipulated above, REACHCENTRUM's liability to COMPANIES under this Agreement shall in no circumstances exceed an amount equal to the amount of this project as specified in the technical proposal included as Annex 1.

9.4 The data gathered with view to registering is believed to be correct. Nevertheless, REACHCENTRUM makes no representations or warranties as to the completeness or accuracy of any of this information in the registration dossier. In addition, REACHCENTRUM cannot guarantee to COMPANIES that information submitted to the relevant authorities will result in official approval, registration or authorisation.

#### **Article 10. Severability**

In the event that any term, condition or provision contained herein shall be held by any court to be unenforceable, illegal, void or contrary to public policy, such term, condition or provision shall be of no effect whatsoever upon the binding force or effectiveness of any of the other provisions hereof, it being the intention of the PARTIES that had they known of such unenforceability, illegality, invalidity or contrariety to public policy, they would have not entered into an Agreement containing all of the other terms, conditions and provisions hereof.

Furthermore, the term, condition or provision held to be unenforceable, illegal, void or contrary to public policy shall be curtailed and limited only to the extent necessary to bring it within the legal requirements.



**Article 11. Notices**

All notices given hereunder shall be delivered in writing in the English language and sent by registered mail and shall be addressed to the PARTIES at their respective addresses as mentioned in this Agreement.

**Article 12. Privacy Notice**

The personal data provided by COMPANIES under this Agreement are processed by REACHCENTRUM in accordance with the provisions of the Belgian Act of 8 December 1992 on the protection of privacy with regard to the processing of personal data. The processing of these data is performed to provide the COMPANIES with the services included in this Agreement.

Subject to the above and except to the extent that communications of personal data to companies whose intervention as data processors, acting on behalf and under the sole control of REACHCENTRUM, is required to accomplish the purposes indicated above, REACHCENTRUM will not disclose, sell, rent or exchange such personal data to any other organization or entity, unless the COMPANY is first notified and expressly agreed with it, or as otherwise required by law. Any data subject has the right to access and restrict its data and, where appropriate, request rectification of any erroneous data relating to him/her. These rights may be exercised by sending an e-mail regarding any questions you may have to [info@reachcentrum.eu](mailto:info@reachcentrum.eu) or by post.

COMPANIES guarantee that they respect the privacy and data protection legislation and warrants REACHCENTRUM against any claim from employees, contractors or other third parties regarding whom COMPANIES would have provided REACHCENTRUM with personal data in the context of this Agreement.

**DONE ON 29 May 2008**


**For REACHCENTRUM**


Signed by A. PERROY





On 29/5/2008

**For COMPANIES**

Company	Seat of Incorporation	Representative	Date	Signature
BK Giulini GmbH	Giulinistrasse 2, 67065 Ludwigshafen am Rhein., Germany	Ytzhak Peretz, Managing Director <i>Roberto Wurst</i> <i>Director of BU BERAPHOS</i>	16.6.08 16.6.08	
Budenheim Chemische Fabrik,	Rheinstrasse 27, D-55257 Budenheim, Germany	Christian Kohlpaintner, CEO and Chairman of the Board		
FMC Foret S.A.	Plaza Xavier Cugat, 2, Edificio C, planta 3ª, Parque de Oficinas Sant Cugat Nord 08174 Sant	Javier Carratalá, Managing Director		



	Cugat del Vallés (Barcelona), Spain			
Prayon SA,	Rue J. Wauters 144, B- 4480 Engis, Belgium,	Jean Braham - Phosphates Direction President		
Thermphos International BV	Harbour 9890, 4389 PD Vlissingen-Oost, The Netherlands	Rob de Ruiter, Director, Joachim Koppers, Business Unit Director	28/7/08 16/07/08	

	Cugat del Vallés (Barcelona), Spain			
Prayon SA,	Rue J. Wauters 144, B- 4480 Engis, Belgium,	Jean Braham - Phosphates Direction President	9.06.08	
Thermphos International BV	Harbour 9890, 4389 PD Vlissingen-Oost, The Netherlands	Rob de Ruiten, Director, Joachim Koppers, Business Unit Director		



data to any other organization or entity, unless the COMPANY is first notified and expressly agreed with it, or as otherwise required by law. Any data subject has the right to access and restrict its data and, where appropriate, request rectification of any erroneous data relating to him/her. These rights may be exercised by sending an e-mail regarding any questions you may have to [info@reachcentrum.eu](mailto:info@reachcentrum.eu) or by post.

COMPANIES guarantee that they respect the privacy and data protection legislation and warrants REACHCENTRUM against any claim from employees, contractors or other third parties regarding whom COMPANIES would have provided REACHCENTRUM with personal data in the context of this Agreement.

**DONE ON [Date]**

**For REACHCENTRUM**

Signed by A. PERROY

On 2 / 19 / 08 / 2008

**ReachCentrum**  
 Avenue E. van Nieuwenhuysse 8  
 BE - 1160 Brussels  
 VAT number: BE 0882 099 201  
 Tel: +32 2 676 74 00  
 Fax: +32 2 676 74 99  
[www.reachcentrum.eu](http://www.reachcentrum.eu)

**For COMPANIES**

Company	Seat of incorporation	Representative	Date	Signature
BK Giuliani GmbH	Giulinistrasse 2, 67065 Ludwigshafen am Rhein., Germany	Ytzhak Peretz, Managing Director		
Budenheim Chemische Fabrik,	Rheinstrasse 27, D-55257 Budenheim, Germany	Christian Kohlpaintner, CEO and Chairman of the Board	M.4.2008 11.4.2008	
FMC Foret S.A.	Plaza Xavier Cugat, 2, Edificio C, planta 3ª, Parque de Oficinas Sant Cugat Nord 08174 Sant Cugat del Vallés (Barcelona), Spain	Javier Carratalá, Managing Director		
Prayon SA,	Rue J. Wauters 144, B-4480 Engis, Belgium,	Jean Braham - Phosphates Direction President		
Thermphos International BV	Harbour 9890, 4389 PD Vlissingen-Oost, The Netherlands	Rob de Ruiten, Director, Joachim Koppers, Business Unit Director		

data to any other organization or entity, unless the COMPANY is first notified and expressly agreed with it, or as otherwise required by law. Any data subject has the right to access and restrict its data and, where appropriate, request rectification of any erroneous data relating to him/her. These rights may be exercised by sending an e-mail regarding any questions you may have to [info@reachcentrum.eu](mailto:info@reachcentrum.eu) or by post.

COMPANIES guarantee that they respect the privacy and data protection legislation and warrants REACHCENTRUM against any claim from employees, contractors or other third parties regarding whom COMPANIES would have provided REACHCENTRUM with personal data in the context of this Agreement.

**DONE ON [Date]**

**For REACHCENTRUM**

Signed by A. PERROY

On 2 / 19 / 08 / 2008

**For COMPANIES**

Company	Seat of incorporation	Representative	Date	Signature
BK Giuliani GmbH	Giulinistrasse 2, 67065 Ludwigshafen am Rhein., Germany	Ytzhak Peretz, Managing Director		
Budenheim Chemische Fabrik,	Rheinstrasse 27, D-55257 Budenheim, Germany	Christian Kohlpaintner, CEO and Chairman of the Board		
FMC Foret S.A.	Plaza Xavier Cugat, 2, Edificio C, planta 3ª, Parque de Oficinas Sant Cugat Nord 08174 Sant Cugat del Vallés (Barcelona), Spain	Javier Carratalá, Managing Director	22/4/08	
Prayon SA,	Rue J. Wauters 144, B-4480 Engis, Belgium,	Jean Braham - Phosphates Direction President		
Thermphos International BV	Harbour 9890, 4389 PD Vlissingen-Oost, The Netherlands	Rob de Ruiten, Director, Joachim Koppers, Business Unit Director		

Annex 1

**TECHNICAL PROPOSAL**

*Consortium Support STPP REACH Consortium, P-1047/MME/O009 (31/1/2008)*



\\rutherford\dfs\  
Dept\REACHCENTRU

A handwritten signature in black ink, appearing to be a stylized 'W' or similar character.

## Annex 2

### **FINANCIAL CONDITIONS**

#### **1. Hourly rates**

The hourly rates of ReachCentrum staff from 01/01/2007 are as follows.  
For staff from external resources a different hourly rate can be applicable and needs to be agreed upon separately.

These are adjusted annually on the 1<sup>st</sup> January on the basis of the Belgian Cost of Living Index.

Head of department	225	EUR
Consortium Manager, level 1	165	EUR
Consortium Manager, level 2	135	EUR
Legal expert	165	EUR
Technical expert	165	EUR
Assistant (Secretary or Clerc)	80	EUR


#### **2. Archiving costs**

The Consortium Archive and being the correspondence address for the Consortium (as described in more detail under phase 5 of the Technical Proposal in Annex 1) is covered by the one time dossier opening provision at the start of the project (article 5.1).

Scanning of paper copies: 40 EUR per 100 pages, including quality check.

#### **3. Invoicing conditions**

REACHCENTRUM will take care and COMPANIES accept the invoicing of the activities conducted under the Agreement in a fair and manageable manner and with costs shared as specified in the STPP Consortium Agreement.






#### 4. Bank account

Payments shall be made exclusively to the following bank account 001 4924627 13 on the name of ReachCentrum. Cost, if any, shall be at the charge of COMPANIES.

<b>Full company Name</b> ReachCentrum SPRL	
<b>Company Address</b> Av. E. Van Nieuwenhuysse 6	<b>Accounts address if different from order address</b> ---
<b>Post Code</b> 1160 Brussels - BELGIUM	<b>IBAN code</b> BE08 0014 9246 2713 <b>BIC code</b> GEBABEBB ---
32-2-6767274	<b>Business Fax Number</b> 32-2-6767499
<b>VAT Number</b> BE 0882 099 291	<b>Currency</b> €
<b>Bank Name and address</b> Fortis Bank  Avenue Louise 200, 1000 Brussels	<b>Sort Code</b> <b>Account Name</b> BE08 0014 9246 2713  <b>Account Number</b> 001-4924627-13



**Annex 3**

**Services offered by SAFEPHARM:**

***DESCRIPTION OF SERVICES No. 25353***



\\rutherford\dfs\  
Dept\REACHCENTRU

A handwritten signature in black ink, appearing to be 'W' or similar, located at the bottom right of the page.

**Annex 4**

**Consultancy Agreement with Chris Thornton**

**P-1047/JKW/C004 (17/3/2008)**

The COMPANIES have agreed to the subcontracting of services to Thornton Environment Communication Consultant TECC Sarl, unless and until a decision otherwise be taken by the Consortium according to the decision making procedures defined in the Consortium Agreement.



\\rutherford\dfs\  
Dept\REACHCENTRU

A handwritten signature in blue ink, appearing to be a stylized 'C' or similar character.